King's Research Portal

DOI:

[10.1016/j.jpsychires.2016.09.010](https://doi.org/10.1016/j.jpsychires.2016.09.010)

Document Version

Peer reviewed version

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Cecil, C., Smith, R. G., Walton, E., Mill, J., McCrory, E. J., & Viding, E. (2016). Epigenetic signatures of childhood abuse and neglect: Implications for psychiatric vulnerability. *Journal of psychiatric research*. <https://doi.org/10.1016/j.jpsychires.2016.09.010>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

**Epigenetic signatures of childhood abuse and neglect:
Implications for psychiatric vulnerability**

SELF-ARCHIVING VERSION

Charlotte A. M. Cecil^{1*}, Rebecca G. Smith^{1,2*}, Esther Walton^{1,3}, Jonathan Mill^{1,3},
Eamon J. McCrory^{4†} & Essi Viding^{4†}

1. Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, SE5 8AF, UK.
2. University of Exeter Medical School, University of Exeter, Exeter, EX1 2LU, UK
3. Department of Psychology, Georgia State University, Atlanta, 30302-5010, USA
4. Division of Psychology and Language Sciences, University College London, London, WC1H 0AP, UK.

*Co-first authors

†Co-senior authors

Citation: Cecil, C.A.M., Smith, R.G., Walton, E., Mill, J., McCrory, E.J. & Viding, E. (In Press). Epigenetic signatures of childhood abuse and neglect: Implications for psychiatric vulnerability Assessment. *Journal of Psychiatric Research*.

Correspondence to: Charlotte Cecil, Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, De Crespigny Park, London, SE5 8AF, UK. Tel: +44 (0)207 848 0389, E-mail: charlotte.cecil@kcl.ac.uk.

Acknowledgements: We would like to thank the young people, teachers and key workers who have taken part in this project. We are grateful to the Urban Academy, Haberdashers' Aske's Hatcham College and Hertswood Academy for their valuable collaboration. We thank Jo Guiney, Yvonne Whelan and Kathryn Hubbard for their assistance with data collection. Research reported in this publication was supported by the Waterloo Foundation (Award Number: R1233/1872; PIs: E.V. and J.M.) and Kids Company charity. C.C. is supported by the Economic and Social Research Council (grant ref: ES/N001273/1). E.W. was supported by the German Research Foundation (Wa 3635/1-1). E.V. is a Royal Society Wolfson Research Merit Award Holder.

Abstract

Childhood maltreatment is a key risk factor for poor mental and physical health. Recently, variation in epigenetic processes, such as DNA methylation, has emerged as a potential pathway mediating this association; yet, the extent to which different forms of maltreatment may be characterized by unique vs shared epigenetic signatures is currently unknown. In this study, we quantified DNA methylation across the genome in buccal epithelial cell samples from a high-risk sample of inner-city youth ($n = 124$; age = 16-24; 53% female), 68% of whom reported experiencing at least one form of maltreatment while growing up. Our analyses aimed to identify methylomic variation associated with exposure to five major types of childhood maltreatment. We found that: (i) maltreatment types differ in the extent to which they associate with methylomic variation, with physical exposures showing the strongest associations; (ii) many of the identified loci are annotated to genes previously implicated in stress-related outcomes, including psychiatric and physical disorders (e.g. *GABBR1*, *GRIN2D*, *CACNA2D4*, *PSEN2*); and (iii) based on gene ontology analyses, maltreatment types not only show *unique* methylation patterns enriched for specific biological processes (e.g. physical abuse and cardiovascular function), but also share a '*common*' epigenetic signature enriched for biological processes related to neural development and organismal growth. A stringent set of sensitivity analyses were also run to identify high-confidence associations. Together, findings lend novel insights into epigenetic signatures of childhood abuse and neglect, point to novel potential biomarkers for future investigation and support a molecular link between maltreatment and poor health outcomes. Nevertheless, it will be important in future to replicate findings, as the use of cross-sectional data and high rates of polyvictimization in our study make it difficult to fully disentangle the shared vs unique epigenetic signatures of maltreatment types. Furthermore, studies will be needed to test the role of potential moderators in the identified associations, including age of onset and chronicity of maltreatment exposure.

Keywords: DNA Methylation; epigenome-wide; child abuse; neglect; maltreatment; stress

Introduction

Childhood maltreatment, encompassing abuse and neglect, is a major public health concern that continues to affect up to one in four children worldwide, with often devastating developmental consequences (WHO, 2014). Children who experience maltreatment are at increased risk for a range of psychiatric problems, including anxiety, depression, post-traumatic stress, and antisocial behaviour (Cicchetti and Toth, 2005). The effects of maltreatment can extend well into adulthood, compromising relationship quality, economic productivity and physical health (Danese *et al.*, 2009).

The theory of latent vulnerability proposes that maltreatment exposure calibrates a range of biological and neurocognitive systems in line with a threatening and unpredictable early environment (McCrory and Viding, 2015). While potentially adaptive in the short term, such changes can increase vulnerability in the long term. Consistent with this view, numerous biological correlates of maltreatment have now been identified, including accelerated cellular ageing, neuroendocrine dysregulation, heightened inflammatory response as well as altered brain structure and function (Danese *et al.*, 2011, McCrory *et al.*, 2012, Shalev *et al.*, 2013). Recent evidence indicates that, as well as affecting common biological pathways, different forms of maltreatment may also exert unique effects. For example, while abuse has been associated with changes in neural circuitry underlying threat processing, neglect has been associated with biological adaptations to low-complexity environments (Sheridan and McLaughlin, 2014).

A key challenge for current research is to understand how, at a molecular level, these environmental exposures are translated into phenotypic variation. Epigenetic processes, such as DNA methylation (DNAm), which control the functional regulation of gene expression are of particular interest in this regard, as mounting evidence suggests they can be modified by environmental factors (Jaenisch and Bird, 2003). For example, animal studies have found that a number of environmental stressors, such as poor maternal care, induce stable alterations in DNAm in the regulatory regions of several HPA axis genes (e.g. the glucocorticoid receptor), which in turn influence responses to future stressors (Turecki and Meaney, 2014). Similarly, a small number of human studies have documented a link between childhood maltreatment and aberrant DNAm in genes important for stress-response, immune function and neurodevelopment (Lutz and Turecki, 2014). DNAm has also been shown to regulate a wide range of neurobiological processes, including neurogenesis, synaptic plasticity, learning and memory (Baker-Andresen *et al.*, 2013, Day *et al.*, 2013) and aberrations in DNAm have been observed in a range of diseased states, including stress-related psychiatric disorders such as post-traumatic stress and major depression (Bergman and Cedar, 2013, Klengel *et al.*, 2014).

To date, most epigenetic studies of maltreatment have focused on variation in the vicinity of a limited set of pre-selected candidate genes (i.e. *GR*, *FKBP5*, *BDNF* and *5-HTT*) (Lutz and Turecki, 2014). As such, little is known about the broader effect of maltreatment on DNAm across the genome. This is a substantial limitation in light of the fact that maltreatment impacts multiple aspects of functioning, across psychological, physical, and social domains. Furthermore, existing studies have primarily examined global maltreatment (Labonte *et al.*, 2012, Prados *et al.*, 2015, Suderman *et al.*, 2014, Yang *et al.*, 2013), so that the extent to which different maltreatment types may have common vs distinct epigenetic signatures is unclear. To address these outstanding questions, we explored the relationship

between DNAm and five types of maltreatment in a sample of high-risk youth, using genome-wide DNAm data drawn from buccal epithelial cells.

Methods and Materials

Participants

The current sample was recruited as part of a larger study examining the effects of developmental adversity on individual functioning ($n = 204$, age range = 16-24 years). Analyses only included participants for whom DNAm data was available ($n = 124$). Youth from deprived inner London areas were recruited through multiple channels including inner-city colleges, internet websites and a charity providing services and support to self-referred youth. The sample was 53% female and ethnically diverse (49% White, 33% Black, 18% other). The study was carried out in accordance with the latest version of the Declaration of Helsinki. The study design was reviewed and approved by the UCL Research Ethics Committee (*ID No*: 2462/001) and all participants provided informed consent prior to participation, after the nature of the procedures had been fully explained. Further details of the sample and recruitment procedures are available elsewhere (Cecil *et al.*, 2014).

Measures

Childhood maltreatment – Childhood maltreatment was assessed using the 28-item, self-report Childhood Trauma Questionnaire (CTQ; Bernstein and Fink, 1998). The CTQ screens for experiences of maltreatment “while growing up” and comprises of 5 continuous subscales: emotional abuse, sexual abuse, physical abuse, emotional neglect and physical neglect. The scales show high internal consistency in our sample ($\alpha = .70 - .97$). For descriptive purposes only, we also classified participants as having experienced maltreatment (i.e. yes/no) if they scored above the ‘Low’ threshold specified by the CTQ manual for at least one maltreatment type. By including ‘I currently feel unsafe at home’ as an additional yes/no item we were able to ascertain that none of the participants in the study were currently vulnerable to violence in the domestic environment (e.g. by family or partner). As such, the present study investigates the effects of childhood (i.e. past) maltreatment.

DNA methylation – DNA was extracted from buccal epithelial cells using procedures described in Freeman *et al.* (2003). 500ng of high molecular weight DNA was subjected to sodium bisulfite conversion using the EZ-DNA methylation kit (Zymo Research, Orange, CA, USA) using the manufacturers standard protocol. DNAm was quantified using the Illumina HumanMethylation450 BeadChip (Illumina, USA) with arrays scanned using an Illumina iScan (software version 3.3.28). The Illumina 450K array interrogates >485,000 probes covering 99% of Reference Sequence (RefSeq) genes, with an average of 17 CpG sites per gene region. As the samples were run in a single batch, there was no need for batch correction. To account for potential chip and position effects, we randomized sample chip allocation and placement on the chip. Initial data quality control was conducted using GenomeStudio (version 2011.1) to determine the status of staining, extension, hybridization, target removal, bisulfite conversion, specificity, non-polymorphic and negative controls. Samples that survived this stage were checked for concordance between their reported and assessed sex and then quantile normalised using the *dasen* function within the *wateRmelon*

package (watermelon_1.0.3; Pidsley *et al.*, 2013) in R. Probes were removed if they were cross-reactive, polymorphic, used for sample identification on the array, had a SNP at the single base extension with a minor allele frequency larger than 5% (i.e. common polymorphisms) or were located on the Y chromosome, leaving a total of 413,239 probes (Chen *et al.*, 2013; Price *et al.*, 2013). DNAm levels are indexed by beta values (ratio of methylated signal divided by the sum of the methylated and unmethylated signal, M/M+U).

Data Analysis

All analyses were performed within the R statistical environment (version 3.0.1). Methylation data was regressed for sex, age and self-reported ethnicity to account for potential confounding effects (Liang and Cookson, 2014). The analysis proceeded in three steps. First, we ran five independent epigenome-wide association analyses – one for each maltreatment type measured – using linear regression models. Probes were considered significant if they survived a False Discovery Rate (FDR) correction of $q < 0.05$. Only maltreatment types that were associated with at least one FDR-corrected probe were carried forward to the next step. Second, we identified which probes were most consistently associated with *all* types of maltreatment, by ranking them in order of average standardized effect size. Third, we examined enriched biological pathways for genes that were associated only with one type of maltreatment vs those that were associated with all maltreatment types, using an optimized gene ontology method that controls for a range of potential confounds, including background probe distribution and gene size (see **OS1** for details). More specifically, genes were considered ‘unique’ if the probes annotated to them were specifically associated with one maltreatment type and none other (i.e. $p < 0.005$ with one type of maltreatment, and $p > 0.05$ with the other two types of maltreatment). Conversely, genes were considered ‘shared’ if probes annotated to them were associated across maltreatment types ($p < 0.05$ consistently across all three forms of maltreatment). To calculate statistical power to detect effects, we used the pwr package with a p-value threshold of $1.00E-06$ to reach 80% power (Tsai & Bell, 2015) in the context of a linear regression model. Results showed that, with a sample size of 124 individuals, we could expect to detect an effect size of ≥ 0.32 , indicating that the study is appropriately powered for detecting medium-to-large effects.

Results

Descriptives and correlations between study variables shown in **Table 1**. Based on the CTQ cut-off, the majority of youth in the current study reported having experienced at least one form of maltreatment while growing up (68%; $n = 84$). The reported experiences were often severe: 75% of physically abused youth were left with bruises or marks as a result of injuries; 50% of sexually abused youth reported being threatened; and 60% of physically neglected youth reported not having enough to eat. Poly-victimization was common, with 74% of maltreated youth reporting two or more forms of maltreatment, consistent with previous studies (Radford *et al.*, 2011).

***** **Table 1** *****

Maltreatment types differ in the extent to which they associate with DNAm variation

We first examined associations between DNAm across the genome and individual maltreatment types (measured continuously). No probes were identified as being differentially methylated at a FDR<0.05 for emotional abuse and emotional neglect (**OS2**); as such, these two types of maltreatment were excluded from further analysis. With regards to other maltreatment types, the number of differentially methylated probes (DMPs) was: 34 for physical abuse, 7 for sexual abuse, and 118 for physical neglect. The 10 top-ranked DMPs for each of these maltreatment types are displayed in **Table 2** (see **OS3** for a complete table of FDR-corrected probes). Associations between DNAm and each maltreatment type are graphically represented in **Figure 1A** (see **OS4** for quantile-quantile plots for each analysis).

Physical abuse: The top-ranked DMP, cg20000641, was significantly hypermethylated with increased exposure to physical abuse ($p=3.54E-11$, $q=1.47E-05$; **Table 2A**, **Figure 1B**). This probe is located in the promoter region of *PSEN2*, a gene encoding a presenilin enzyme involved in amyloid precursor protein processing that is robustly implicated in Alzheimer's disease (O'Brien and Wong, 2011). Two top-ranked probes were annotated to *SMC1A* (cg02353937: $p = 2.90E-09$, $q=7.89E-04$; cg22311608: $p = 8.45E-08$, $q=0.01$), a gene involved in chromosomal maintenance and DNA repair (Kim *et al.*, 2002). Also of interest were DMPs annotated to genes highly expressed in the brain, including *SHC2* (cg19736040: $p = 1.38E-06$, $q=0.05$), involved in neurotrophin-activated Trk receptor signaling within cortical neurons and synaptic plasticity in the hippocampus (Epa *et al.*, 2004), and *IMPACT* (cg03013329: $p = 2.10E-06$, $q=0.05$), encoding a protein that facilitates neurite outgrowth and modulates kinase activation in neurons (Roffe *et al.*, 2013).

Sexual abuse: The top-ranked DMP associated with sexual abuse (cg17106653, $p=4.16E-09$, $q=1.72E-03$; **Table 2B**, **Figure 1B**) was located in the promoter region of the glutamate receptor *GRIN2D*, a gene implicated in CNS plasticity and excitatory synaptic transmission (Traynelis *et al.*, 2010). Other annotated genes of interest include *MGMT* (cg26528551: $p = 6.84E-08$, $q=0.01$) implicated in DNA repair mechanisms and *DIP2C* (cg23983710: $p = 5.83E-07$, $q=0.03$), a gene primarily expressed in the brain but whose biological function is poorly understood.

Physical Neglect: The top-ranked DMP associated with physical neglect was cg00691266 in *EVPN* ($p=1.01E-07$, $q=0.01$; **Table 2C**), encoding a protein involved in epidermal growth. Several probes were annotated to genes related to brain function, including *SYNJ2* (cg27083825: $p = 1.02E-07$, $q=0.01$; **Figure 1B**), involved in nervous system development and neuronal vesicle uncoating (Montesinos *et al.*, 2005); and *GABBR1* (cg18116160: $p = 4.01E-07$, $q = 0.02$) a GABA class B receptor important for inhibitory synaptic transmission (Kumar *et al.*, 2013). Probes annotated to genes involved in histone regulation were also identified, including *SETDB1* (cg17918089: $p = 1.14E-07$, $q=0.01$), *JADE1* (cg09863040: $p = 2.10E-07$, $q=0.01$), and *HIST1H1A* (cg08054907: $p = 5.12E-07$, $q=0.02$).

Sensitivity analyses: Given that quantile-quantile plots from our epigenome-wide analyses indicated skewing of significant results (**OS4**), we carried out a set of sensitivity analyses to test the robustness of the identified associations. **First**, to minimize the influence of unknown

confounders, we ran a surrogate variable analysis (sva package in R; Leek et al., 2012) that enabled us to identify unwanted sources of variation in our DNA methylation data. The analysis identified 11 surrogate variables representing different sources of variation/noise. We then re-ran associations between each form of maltreatment and DNAm additionally controlling for these 11 surrogate variables. While variations in significance levels were observed across a number of probes (both increases and decreases in p-value), all sites remained significantly associated with maltreatment severity ($p < 0.05$), with the exception of two probes related to physical neglect (see **OS5**). A total of 45 sites (physical abuse: $n = 26$; sexual abuse: $n = 7$ and physical neglect: $n = 12$) also survived genome-wide correction ($q < 0.05$). Overall, associations with physical and sexual abuse were the least affected by unmeasured confounding, and those with physical neglect were the most affected.

Second, to examine the potential influence of outliers, we applied the winsorize function within the robustHD package to the DNAm data and reran epigenome-wide analyses, controlling for covariates. The winsorizing method uses censoring rather than exclusion, which is preferable with small sample sizes (Sheskin, 2003). Specifically, for each probe, values $<5\%$ or $>95\%$ of the score distribution were transformed to match the closest value within this percentile, which enables scores to maintain their relative weight without exerting an undue influence on the linear regression model. Although the vast majority of associations remained significant after winsorizing (97% ; $p < 0.05$), none of the transformed DMPs survived genome-wide correction ($q > 0.05$; **OS5**). It is important to note, however, that this sensitivity analysis is highly conservative as it transforms, for each probe, scores at the tail ends of the distribution regardless of presence or absence of outliers. As such, this approach reduces the range of methylation scores across all probes, resulting in more limited variability.

Third, we performed bootstrapping as a complement to winsorizing using Mplus (version 6.1.1; Muthen & Muthen, 2011). Bootstrapping is advantageous with small samples as it derives an approximation of the sampling distribution via repeated resampling of the available data to yield bias-corrected 95% confidence intervals (CI). Associations were considered significant if bootstrapped 95% CIs (10,000 times) did not cross zero. The number of DMPs that survived bootstrapping were: $n = 29$ for physical abuse, $n = 1$ for sexual abuse, and $n = 108$ for physical neglect. Hence, sites associated with sexual abuse were the most affected by this sensitivity analysis, potentially reflecting the low number of individuals scoring high on this exposure, resulting in more extreme values.

Based on the above results, we compiled a list of high-confidence associations (see **OS5**), in order to highlight DMPs that were the most robustly implicated across the three sensitivity analyses and as such may be particularly promising candidates for prioritization in future studies. High-confidence associations were defined as having (i) an SVA q-value < 0.05 , (ii) a winsorized p -value < 0.05 , and (iii) significant bootstrapped 95% CIs. The resulting number of high-confidence associations for each exposure were: $n = 20$ for physical abuse, $n = 1$ for sexual abuse and $n = 10$ for physical neglect.

***** **Table 2** *****

***** **Figure 1** *****

Variability in certain DNAm loci consistently associate with all maltreatment types

The top 20 hyper- and hypomethylated DMPs consistently associated with all three maltreatment types (i.e. physical abuse, sexual abuse and neglect) are shown in **Table 3**, ranked by average standardized effect size. The top-ranked hypermethylated probe, cg08796898 (**Figure 1C**), is located in *HUWE1*, an important regulator of neural proliferation linked to intellectual disability (Vandewalle *et al.*, 2013). Other genes annotated to hypermethylated probes include: (i) *CACNA2D4* (cg27516159), identified as a shared risk locus for multiple psychiatric disorders (Smollen *et al.*, 2013); (ii) *WBSCR17* (cg25579180), a gene widely expressed in the brain and associated with neurodevelopmental delay (Nakamura *et al.*, 2005); (iii) *LRP4* (cg12627354), involved in neuromuscular junction maintenance and acetylcholine signaling; and (iv) *GRB10* (cg26163537), an insulin modulator.

With regard to hypomethylated probes, we identified multiple markers annotated to genes that are involved in response to environmental stimuli, including: (i) two probes in *RPTOR* (cg07870603, cg09596252), a gene involved in cell growth regulation in response to climatic factors, nutrient and insulin levels (Sun *et al.*, 2010); and (ii) *GJD3* (cg22896075), which encodes a connexin thought to facilitate environmental adaptation by regulating physiological processes such as neuronal excitability (Belousov and Fontes, 2013). Another gene, *DNAJB6* (cg27496299; **Figure 1C**), has been found to reduce cellular toxicity and act as a molecular chaperone for neuronal proteins, including huntingtin (Mansson *et al.*, 2014). Finally, *TIAM2* (cg01786585) has been implicated in neurogenesis, particularly in the hippocampus, as well as promoting neural migration in the cerebral cortex (Chiu *et al.*, 1999).

DNAm variation implicates both maltreatment-specific and shared functional pathways

As a final step, we examined enriched biological pathways for genes that were either (i) annotated to DMPs that associated with only *one* type of maltreatment ($p < 0.005$); or (ii) annotated to DMPs that associated with *all* maltreatment types ($p < 0.05$ across physical abuse, sexual abuse and neglect). Following these criteria, neglect showed ‘unique’ epigenetic variation in probes annotated to a larger number of genes ($n = 329$) than physical ($n = 119$) and sexual abuse ($n = 47$). A considerable proportion of genes showed epigenetic variation across all three maltreatment type (i.e. ‘shared’ genes; $n = 2,348$; consistent direction of effects).

Gene ontology analyses were performed for the above sets of genes (except sexual abuse, due to the low number of annotated genes), controlling for a range of potential confounds, including background probe distribution and gene size (**Figure 2**; see **OS1** for details). Results indicated that genes associated with DNAm variation specific to *physical abuse* were enriched for biological processes including cardiovascular function (e.g. cardiac muscle hypertrophy, heart rate), fear response, and wound healing ($1.04\text{E-}12 < p < 7.65\text{E-}03$), while those associated with *neglect*-specific variation were enriched for regulation of cholesterol efflux, as well as processes related to cellular function and metabolism ($2.91\text{E-}11 < p < 1.04\text{E-}02$; see **OS6** for a full list of terms). In contrast, genes associated with epigenetic variation *shared* across maltreatment types were significantly enriched for biological processes primarily related to regulation of nervous system development (e.g. neurogenesis, glial proliferation, neurotransmitter biosynthesis, oligodendrocyte development) and

organismal growth (e.g. organ morphogenesis, negative regulation of growth, response to growth factor; see **OS7** for a full list of terms; $4.20\text{E-}10 < p < 1.44\text{E-}02$).

***** **Figure 2** *****

Discussion

This study is the first to characterize genome-wide DNAm patterns associated with different types of childhood abuse and neglect. Strengths include the availability of quantitative data on a range of different exposures, the inclusion of a sample of youth featuring high rates of adversity, and the analysis of methylome-wide data. Here, we highlight three key findings: (i) specific types of maltreatment, particularly physical exposures, are associated with DNAm variation at multiple loci; (ii) many of the identified loci are annotated to genes previously implicated in psychiatric and medical disorders; and (iii) gene ontology analyses indicate that, while maltreatment types show distinct patterns of methylomic variation, they also share a common epigenetic ‘signature’ enriched for biological processes related to neural development and organismal growth. The use of stringent sensitivity analyses further enabled us to identify high-confidence associations, which point to promising candidate loci for prioritization in future studies.

Findings lend novel insights into the relationship between maltreatment and DNA methylation

Of the maltreatment types investigated, we found that physical exposures – including physical abuse, sexual abuse and physical neglect – all associated with epigenetic variation at multiple loci, with neglect showing the largest number of DMPs after genome-wide correction (despite having comparable prevalence rates to physical abuse). In contrast, no significant loci were identified for emotional abuse and emotional neglect (after multiple correction). This was unexpected given that emotional abuse, in particular, has been recognized as an important independent predictor of poor individual functioning (Rees, 2010). Consequently, more work is required to clarify whether results reflect a true lack of associations or whether other factors may be at play (e.g. challenges with the operationalization of emotional abuse; polyepigenetic effects of smaller magnitude; tissue specificity). It is also interesting to note that we identified an unexpectedly high number of associations between maltreatment types and DNAm sites located on the X-chromosome. Given that sex was controlled for in the analyses, these results suggest that maltreatment exposure may influence these DNAm sites similarly for boys and girls. Although sex differences were not examined in the present study due to sample size limitations, it will be of interest in future to test the potential role of sex in the relationship between maltreatment and DNAm.

Comparability with previous findings on maltreatment and DNAm is limited by the fact that, while other epigenetic studies have examined maltreatment as a global construct, we investigated DNA methylation profiles associated with specific forms of abuse and neglect. As such, a strict test of replication was not possible. Furthermore, past studies have varied widely on factors such as choice of tissue (e.g. saliva, blood or brain), DNAm platform (e.g.

Illumina 450k vs MeDIP), methodology (e.g. filtering of probes, covariates), maltreatment measure (e.g. self-report vs official records), population (e.g. community vs clinical) and sample characteristics (e.g. age, sex), making it difficult to assess our findings in the context of previous work in the area.

Nevertheless, we note here two of the most similar studies to ours, which have also used the Illumina 450k platform in peripheral tissues to investigate methylome-wide associations with childhood maltreatment. The first study (Yang *et al.* 2013) used DNA from saliva specimens to compare methylomic differences between a sample of maltreated and non-maltreated children, using a case-control design. The second study (Prados *et al.* 2015) used blood samples to compare DNAm patterns in adults with borderline personality disorder and exposure to high levels of childhood maltreatment vs adults with major depression disorder who had experienced low levels of childhood maltreatment (assessed using the same measure as our study, the CTQ). Comparing findings from our respective genome-wide analyses, we identified one overlapping DNAm site that was associated with maltreatment (after genome-wide correction) across both our study and Yang *et al.*'s (*CILP2*_{cg01487433}), and no overlap with the DNAm sites reported in Prados *et al.*'s study. In addition, we identified several overlapping genes between studies (29 with Yang's *et al.*'s study; 1 with Prados *et al.*'s study) that had at least one genome-wide significant probe annotated to them. However, because these genes varied widely in DNAm probe coverage, it is unclear whether they were identified across studies because they robustly associate with maltreatment or because they may have had a larger number of DNAm probes annotated to them. As a whole, DMPs were found to differ between our study and previous ones. As such, it will be important in future to establish whether discrepancies may reflect the examination of global vs individual forms of maltreatment, methodological differences between studies or the presence of false positives, all issues that should be considered when interpreting the present findings.

We note that the use of sensitivity analyses in the present study (surrogate variable analysis, winsorizing and bootstrapping) enabled us to identify a subset of DMPs that were most robustly associated with maltreatment exposure (i.e. 'high-confidence associations'; $n = 31$, 20% of total DMP set), and consequently may show promise as candidate loci for further investigation. Of interest, DMPs associated with physical neglect were most affected by the surrogate variable analysis, suggesting that the methylomic signature of this maltreatment type may in part reflect other sources of variability (e.g. genetic architecture, unmeasured exposures, confounding sources). In contrast, DMPs associated with sexual abuse were the most affected by the winsorizing and bootstrapping analyses, which may instead reflect the low number of individuals reporting high levels of this exposure. In general, associations between DNAm and physical abuse were the most robust, with 59% of DMPs ($n = 20$) classified as high-confidence. While these findings may be used in future to inform locus-prioritization, it is important to note that the identification of high-confidence associations was based on a stringent set of criteria, so that the extent to which 'lower-confidence' DMPs may be robustly associated with maltreatment exposure will still need to be established via replication in independent samples.

The identified DNA methylation markers support a molecular link between maltreatment and poor health outcomes

Our analyses identified multiple DMPs annotated to genes previously associated with psychiatric and medical disorders. The top-ranked DMP for physical abuse was located in the promoter region of *PSEN2*, a gene implicated in neurodegeneration and Alzheimer's disease (O'Brien and Wong, 2011). Although we are not aware of any study directly investigating the link between physical abuse and these conditions in advanced age, early life factors, including stress and the quality of the maternal relationship, have been associated with both neuropsychological impairment and dementia (Pechtel and Pizzagalli, 2011, Vaillant *et al.*, 2014). It will therefore be of interest to test whether *PSEN2* methylation mediates the effect of abuse on cognitive function and neurodegenerative risk. Maltreatment-associated DNAm changes were additionally identified in a number of other genes implicated in cognitive deficit and intellectual disability, including *HUWE1*, *WBSCR17* and *SMC1A* (Deardorff *et al.*, 2007, Nakamura *et al.*, 2005, Vandewalle *et al.*, 2013).

Findings also suggest a role of other loci previously implicated in psychopathology. Notably, one of the most hypermethylated markers across maltreatment types was located in *CACNA2D4*. Genetic variation within this gene has been identified as a *shared* risk locus for multiple psychiatric conditions that are associated with experience of childhood adversity, including attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (Smollen *et al.*, 2013). Interestingly, expression levels of this gene have been found to modulate neural hippocampal activity during emotional processing as well as prefrontal activity during executive tasks (Bigos *et al.*, 2010) – functional patterns that are disrupted in maltreated individuals (Hart and Rubia, 2012). Furthermore, genetic variation in *SYNJ2*, another gene identified in our epigenome-wide analyses, has been linked to corpus callosum abnormalities (Edwards *et al.*, 2014), which are robustly associated with maltreatment (McCrary *et al.*, 2012). Other psychopathology-relevant genes included glutamate and GABA receptors (*GRIN2D*, *GABBR1*), which play a key role in excitatory and inhibitory neurotransmission, respectively (Kumar *et al.*, 2013, Yamamoto *et al.*, 2015). Prospective studies will be needed to explicitly test whether the DNAm sites identified in the present study associate with psychopathological outcomes and, if so, whether they may mediate the influence of abuse and neglect on later mental health.

Gene ontology analyses contribute to a better understanding of biological pathways that may be affected by childhood abuse and neglect.

Gene ontology analyses were performed to explore biological pathways that may be uniquely affected by specific forms of maltreatment vs those 'shared' across maltreatment types. With regards to 'maltreatment-specific' pathways, we found that physical abuse was primarily associated with DNAm variation in the vicinity of genes enriched for cardiovascular processes, including regulation of heart rate and myocardial hypertrophy. This is consistent with evidence from epidemiological studies of elevated risk of heart disease among individuals who were physically abused as children, even after controlling for other childhood stressors, adult lifestyle factors and unhealthy behaviors (Fuller-Thomson *et al.*,

2010, Springer *et al.*, 2007). Other enriched processes of interest related to wound healing, fear response and regulation of stress-activated protein kinase signaling. These pathways are in line with growing evidence from neuroendocrine and imaging studies of an association between physical abuse, HPA axis dysregulation and altered threat processing at neural and behavioral levels (Carpenter *et al.*, 2011, McCrory *et al.*, 2011, Turecki and Meaney, 2014). In contrast, the most enriched biological process specifically linked to neglect was regulation of cholesterol efflux, followed by other processes including DNA damage response, ribosomal function and zymogen activation. Although this finding necessitates replication, it is worth noting that these processes have been shown to respond to diet and nutrient availability (Fenech and Bonassi, 2011, Mizushima *et al.*, 2004), which may be particularly compromised in youth who have experienced neglect (as evidenced in our sample). Together, our data suggest that physical abuse and neglect may affect epigenetic regulation of separate biological pathways, which may in part underlie differential effects observed at a phenotypic level (Sheridan and McLaughlin, 2014). Sexual abuse could not be examined due to the limited number of genes showing ‘unique’ epigenetic variation, which may reflect lack of power due to lower prevalence rates in our sample.

In addition to showing specific epigenetic variation, maltreatment types were also found to share a common methylomic signature, primarily enriched for processes related to neurodevelopment and organismal growth. This is consistent with a large body of evidence from animal and human studies documenting the impact of maltreatment and early life stress on brain structure, function and development. For example, maltreatment has been consistently associated with reduced volume of the corpus callosum, prefrontal cortex and hippocampus (Hart and Rubia, 2012, McCrory *et al.*, 2012). Broader developmental delay and growth failure is also well established amongst maltreated children (Leslie *et al.*, 2005, Olivan, 2003). Findings are also in line with previous epigenetic studies that have documented an association between global maltreatment exposure and DNAm changes in genes enriched for neural (e.g. Labonte *et al.*, 2012: ‘*neuron projection*’, ‘*dendrite*’; Yang *et al.*, 2013: ‘*neurogenesis*’, ‘*axonal guidance*’) and developmental (e.g. Suderman *et al.*, 2014: ‘*multicellular organismal development*’) processes. In future, it will be important to explore whether epigenetic regulation of these ‘core’ processes in response to maltreatment is functionally relevant at a transcriptomic level, and whether they relate directly to other biological markers of neurodevelopment and growth, such as imaging data and markers of cellular ageing.

Limitations and future directions

The current findings should be interpreted in light of a number of important limitations. First, although rates of maltreatment in our sample were high, analyses were based on a modestly sized group of inner-city youth, which precluded the possibility of addressing more nuanced research questions (e.g. sex differences). Furthermore, our assessment of maltreatment was based on self-reports that lacked information regarding maltreatment timing and duration, both of which are likely to moderate the association between maltreatment and DNA methylation. In future, it will be important to replicate findings using larger samples, ideally

featuring externally-validated maltreatment histories that will make it possible to investigate how DNAm patterns may vary by age of onset and chronicity of exposure to different forms of maltreatment. Second, due to the high rates of polyvictimization in our sample, it was not feasible to compare methylomic patterns between individuals who experienced single forms of maltreatment in isolation. Instead, we examined methylome-wide associations for each maltreatment type dimensionally, and then explored the presence of unique vs shared signatures at a functional pathway level, as opposed to a DNAm site level. Even though associations were always strongest for the maltreatment type under investigation, it is therefore still possible that the identified sites may have in part reflected the combined effect of exposure to multiple maltreatment types. Furthermore, the identification of unique vs shared biological pathways linked to maltreatment were based on gene ontology analyses, which can be susceptible to bias (Timmons *et al.*, 2015), and consequently will necessitate replication. Third, data on smoking status and medication use were not available in the present study. As these exposures have been shown to alter DNAm patterns (particularly in blood; Gao *et al.*, 2015), it will be important to replicate findings controlling for these potential confounders. It is noteworthy, however, that none of the DNAm sites identified in the present study overlapped with those found to be robustly affected by smoking in a recent systematic review (i.e. DNAm sites associated with smoking in at least three independent reports; Gao *et al.*, 2015). Fourth, findings were based on DNAm from buccal cell samples and can thus only be considered to represent biomarkers of exposure. Although buccal epithelial cells have been shown to converge more strongly with brain methylation patterns compared to other peripheral tissues (e.g. blood; Smith *et al.*, 2015), further investigation will be needed to establish the relevance of our findings to the brain. Because we did not have access to RNA samples in the present study, we were also unable to establish the extent to which the identified DNAm sites associate with gene expression levels. As such, the analysis of transcriptomic data will be important for assessing the functional significance of the observed DNAm changes. Finally, the cross-sectional nature of the study meant that we were unable to establish the causal role of the identified DMPs. Longitudinal assessments featuring repeated DNAm measures will be needed to explore prospective interrelations between maltreatment exposure, DNAm and developmental outcomes.

Conclusions

The current findings shed new light on how maltreatment may alter epigenetic mechanisms that regulate gene expression, providing a possible biological link between early adversity and poor health outcomes. Different forms of maltreatment were found to have distinct as well as shared signatures, pointing to a complex relationship between the nature of early adverse experience and multiple biological processes relevant for healthy normal development.

References

- Baker-Andresen, D., Ratnu, V. S. & Bredy, T. W. 2013. Dynamic DNA methylation: a prime candidate for genomic metaplasticity and behavioral adaptation. *Trends Neurosci* 36, 3-13.
- Belousov, A. B. & Fontes, J. D. 2013. Neuronal gap junctions: making and breaking connections during development and injury. *Trends Neurosci* 36, 227-36.
- Bergman, Y. & Cedar, H. 2013. DNA methylation dynamics in health and disease. *Nat Struct Mol Biol* 20, 274-81.
- Bernstein, D. P. & Fink, L. 1998. Childhood trauma questionnaire: A retrospective self-report manual. San Antonio.
- Bigos, K. L., Mattay, V. S., Callicott, J. H., Straub, R. E., Vakkalanka, R., Kolachana, B., Hyde, T. M., Lipska, B. K., Kleinman, J. E. & Weinberger, D. R. 2010. Genetic variation in CACNA1C affects brain circuitries related to mental illness. *Arch Gen Psychiatry* 67, 939-45.
- Carpenter, L., Shattuck, T., Tyrka, A., Geraciotti, T. & Price, L. 2011. Effect of childhood physical abuse on cortisol stress response. *Psychopharmacology* 214, 367-375.
- Cecil, C. A., Viding, E., Barker, E. D., Guiney, J. & McCrory, E. J. 2014. Double disadvantage: The influence of childhood maltreatment and community violence exposure on adolescent mental health. *J Child Psychol Psychiatry*.
- Chen, Y. A., Lemire, M., Choufani, S., Butcher, D. T., Grafodatskaya, D., Zanke, B. W., Gallinger, S., Hudson, T. J. & Weksberg, R. 2013. Discovery of cross-reactive probes and polymorphic CpGs in the Illumina Infinium HumanMethylation450 microarray. *Epigenetics* 8, 203-9.
- Chiu, C. Y., Leng, S., Martin, K. A., Kim, E., Gorman, S. & Duhl, D. M. 1999. Cloning and characterization of T-cell lymphoma invasion and metastasis 2 TIAM2, a novel guanine nucleotide exchange factor related to TIAM1. *Genomics* 61, 66-73.
- Cicchetti, D. & Toth, S. L. 2005. Child Maltreatment. *Annual Review of Clinical Psychology* 1, 409-438.
- Danese, A., Caspi, A., Williams, B., Ambler, A., Sugden, K., Mika, J., Werts, H., Freeman, J., Pariante, C. M., Moffitt, T. E. & Arseneault, L. 2011. Biological embedding of stress through inflammation processes in childhood. *Mol Psychiatry* 16, 244-6.
- Danese, A., Moffitt, T. E., Harrington, H., Milne, B. J., Polanczyk, G., Pariante, C. M., Poulton, R. & Caspi, A. 2009. Adverse childhood experiences and adult risk factors for age-related disease: depression, inflammation, and clustering of metabolic risk markers. *Arch Pediatr Adolesc Med* 163, 1135-43.
- Day, J. J., Childs, D., Guzman-Karlsson, M. C., Kibe, M., Moulden, J., Song, E., Tahir, A. & Sweatt, J. D. 2013. DNA methylation regulates associative reward learning. *Nat Neurosci* 16, 1445-52.
- Deardorff, M. A., Kaur, M., Yaeger, D., Rampuria, A., Korolev, S., Pie, J., Gil-Rodriguez, C., Arnedo, M., Loeys, B., Kline, A. D., Wilson, M., Lillquist, K., Siu, V., Ramos, F. J., Musio, A., Jackson, L. S., Dorsett, D. & Krantz, I. D. 2007. Mutations in cohesin complex members SMC3 and SMC1A cause a mild variant of cornelia de Lange syndrome with predominant mental retardation. *Am J Hum Genet* 80, 485-94.

- Edwards, T. J., Sherr, E. H., Barkovich, A. J. & Richards, L. J. 2014. Clinical, genetic and imaging findings identify new causes for corpus callosum development syndromes.
- Epa, W. R., Markovska, K. & Barrett, G. L. 2004. The p75 neurotrophin receptor enhances TrkA signalling by binding to Shc and augmenting its phosphorylation. *J Neurochem* 89, 344-53.
- Fenech, M. & Bonassi, S. 2011. The effect of age, gender, diet and lifestyle on DNA damage measured using micronucleus frequency in human peripheral blood lymphocytes. *Mutagenesis* 26, 43-9.
- Freeman, B., Smith, N., Curtis, C., Hockett, L., Mill, J. & Craig, I. W. 2003. DNA from buccal swabs recruited by mail: evaluation of storage effects on long-term stability and suitability for multiplex polymerase chain reaction genotyping. *Behav Genet* 33, 67-72.
- Fuller-Thomson, E., Brennenstuhl, S. & Frank, J. 2010. The association between childhood physical abuse and heart disease in adulthood: findings from a representative community sample. *Child Abuse Negl* 34, 689-98.
- Gao, X., Jia, M., Zhang, Y., Breitling, L. P., & Brenner, H. 2015. DNA methylation changes of whole blood cells in response to active smoking exposure in adults: a systematic review of DNA methylation studies. *Clinical epigenetics*, 7(1), 1.
- Hart, H. & Rubia, K. 2012. Neuroimaging of child abuse: a critical review. *Front Hum Neurosci* 6, 52.
- Houtepen, L. C., van Bergen, A. H., Vinkers, C. H., & Boks, M. P. 2016. DNA methylation signatures of mood stabilizers and antipsychotics in bipolar disorder. *Epigenomics*, 8(2), 197-208.
- Jaenisch, R. & Bird, A. 2003. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. *Nat Genet* 33 Suppl, 245-54.
- Johnson, W. E., Li, C. & Rabinovic, A. 2007. Adjusting batch effects in microarray expression data using empirical Bayes methods. *Biostatistics* 8, 118-27.
- Kim, S. T., Xu, B. & Kastan, M. B. 2002. Involvement of the cohesin protein, Smc1, in Atm-dependent and independent responses to DNA damage. *Genes Dev* 16, 560-70.
- Klengel, T., Pape, J., Binder, E. B. & Mehta, D. 2014. The role of DNA methylation in stress-related psychiatric disorders. *Neuropharmacology* 80, 115-32.
- Kumar, K., Sharma, S., Kumar, P. & Deshmukh, R. 2013. Therapeutic potential of GABAB receptor ligands in drug addiction, anxiety, depression and other CNS disorders. *Pharmacol Biochem Behav* 110, 174-84.
- Labonte, B., Suderman, M., Maussion, G., Navaro, L., Yerko, V., Mahar, I., Bureau, A., Mechawar, N., Szyf, M., Meaney, M. J. & Turecki, G. 2012. Genome-wide epigenetic regulation by early-life trauma. *Arch Gen Psychiatry* 69, 722-31.
- Leek, J.T., Johnson, W.E., Parker, H.S., Jaffe, A.E. and Storey, J.D., 2012. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. *Bioinformatics* 28, 882-883.
- Leslie, L. K., Gordon, J. N., Meneken, L. E. E., Premji, K., Michelmores, K. L. & Ganger, W. 2005. The Physical, Developmental, and Mental Health Needs of Young Children in Child Welfare by Initial Placement Type. *Journal of developmental and behavioral pediatrics* : JDBP 26, 177-185.

- Liang, L. & Cookson, W. O. C. 2014. Grasping nettles: cellular heterogeneity and other confounders in epigenome-wide association studies. *Human Molecular Genetics* 23, R83-R88.
- Lutz, P. E. & Turecki, G. 2014. DNA methylation and childhood maltreatment: from animal models to human studies. *Neuroscience* 264, 142-56.
- Mansson, C., Kakkar, V., Monsellier, E., Sourigues, Y., Harmark, J., Kampinga, H. H., Melki, R. & Emanuelsson, C. 2014. DNAJB6 is a peptide-binding chaperone which can suppress amyloid fibrillation of polyglutamine peptides at substoichiometric molar ratios. *Cell Stress Chaperones* 19, 227-39.
- McCrory, E., De Brito, S. A. & Viding, E. 2012. The link between child abuse and psychopathology: a review of neurobiological and genetic research. *J R Soc Med* 105, 151-6.
- McCrory, E. J., De Brito, S. A., Sebastian, C. L., Mechelli, A., Bird, G., Kelly, P. A. & Viding, E. 2011. Heightened neural reactivity to threat in child victims of family violence. *Curr Biol* 21, R947-8.
- McCrory, E. J. & Viding, E. 2015. The theory of latent vulnerability: Reconceptualizing the link between childhood maltreatment and psychiatric disorder. *Dev Psychopathol* 27, 493-505.
- Mizushima, N., Yamamoto, A., Matsui, M., Yoshimori, T. & Ohsumi, Y. 2004. In Vivo Analysis of Autophagy in Response to Nutrient Starvation Using Transgenic Mice Expressing a Fluorescent Autophagosome Marker. *Molecular Biology of the Cell* 15, 1101-1111.
- Montesinos, M. L., Castellano-Munoz, M., Garcia-Junco-Clemente, P. & Fernandez-Chacon, R. 2005. Recycling and EH domain proteins at the synapse. *Brain Res Brain Res Rev* 49, 416-28.
- Muthen LK, Muthen BO. MPLUS user's guide, 1998-2010 (6th edn). Los Angeles, CA: Muthen & Muthen; 2011.
- Nakamura, N., Toba, S., Hirai, M., Morishita, S., Mikami, T., Konishi, M., Itoh, N. & Kurosaka, A. 2005. Cloning and expression of a brain-specific putative UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferase gene. *Biol Pharm Bull* 28, 429-33.
- O'Brien, R. J. & Wong, P. C. 2011. Amyloid Precursor Protein Processing and Alzheimer's Disease. *Annual review of neuroscience* 34, 185-204.
- Olivan, G. 2003. Catch-up growth assessment in long-term physically neglected and emotionally abused preschool age male children. *Child Abuse Negl* 27, 103-8.
- Pechtel, P. & Pizzagalli, D. A. 2011. Effects of early life stress on cognitive and affective function: an integrated review of human literature. *Psychopharmacology Berl* 214, 55-70.
- Pidsley, R., CC, Y. W., Volta, M., Lunnon, K., Mill, J. & Schalkwyk, L. C. 2013. A data-driven approach to preprocessing Illumina 450K methylation array data. *BMC Genomics* 14, 293.
- Prados, J., Stenz, L., Courtet, P., Prada, P., Nicastro, R., Adouan, W., Guillaume, S., Olie, E., Aubry, J. M., Dayer, A. & Perroud, N. 2015. Borderline personality disorder and childhood maltreatment: a genome-wide methylation analysis. *Genes Brain Behav* 14, 177-88.

- Price, E. Magda, Allison M. Cotton, Lucia L. Lam, Pau Farré, Eldon Emberly, Carolyn J. Brown, Wendy P. Robinson, and Michael S. Kobor. "Additional annotation enhances potential for biologically-relevant analysis of the Illumina Infinium HumanMethylation450 BeadChip array." *Epigenetics & chromatin* 6, no. 1 (2013): 1.
- Radford, L., Corral, S., Bradley, C., Fisher, H., Bassett, C., Howatt, N. & Collishaw, S. 2011. Child abuse and neglect in the UK today. NSPCC.
- Rees, C. A. 2010. Understanding emotional abuse. *Archives of Disease in Childhood* 95, 59-67.
- Roffe, M., Hajj, G. N., Azevedo, H. F., Alves, V. S. & Castilho, B. A. 2013. IMPACT is a developmentally regulated protein in neurons that opposes the eukaryotic initiation factor 2alpha kinase GCN2 in the modulation of neurite outgrowth. *J Biol Chem* 288, 10860-9.
- Shalev, I., Moffitt, T. E., Sugden, K., Williams, B., Houts, R. M., Danese, A., Mill, J., Arseneault, L. & Caspi, A. 2013. Exposure to violence during childhood is associated with telomere erosion from 5 to 10 years of age: a longitudinal study. *Mol Psychiatry* 18, 576-81.
- Sheridan, M. A. & McLaughlin, K. A. 2014. Dimensions of early experience and neural development: deprivation and threat. *Trends Cogn Sci* 18, 580-5.
- Sheskin, David J. *Handbook of parametric and nonparametric statistical procedures*. crc Press, 2003.
- Smith, A. K., Kilaru, V., Klengel, T., Mercer, K. B., Bradley, B., Conneely, K. N., Ressler, K. J. & Binder, E. B. 2015. DNA extracted from saliva for methylation studies of psychiatric traits: evidence tissue specificity and relatedness to brain. *Am J Med Genet B Neuropsychiatr Genet* 168B, 36-44.
- Smoller, JW, Craddock, N, Kendler, K, Lee, PH, Neale, BM, Nurnberger, JI, Ripke, S, Santangelo, S, & Sullivan, PF 2013. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. *Lancet* 381, 1371-9.
- Springer, K. W., Sheridan, J., Kuo, D. & Carnes, M. 2007. Long-term physical and mental health consequences of childhood physical abuse: results from a large population-based sample of men and women. *Child Abuse Negl* 31, 517-30.
- Suderman, M., Borghol, N., Pappas, J. J., Pinto Pereira, S. M., Pembrey, M., Hertzman, C., Power, C. & Szyf, M. 2014. Childhood abuse is associated with methylation of multiple loci in adult DNA. *BMC Med Genomics* 7, 13.
- Sun, C., Southard, C., Witonsky, D. B., Kittler, R. & Di Rienzo, A. 2010. Allele-specific down-regulation of RPTOR expression induced by retinoids contributes to climate adaptations. *PLoS Genet* 6, e1001178.
- Timmons, J. A., Szkop, K. J. & Gallagher, I. J. 2015. Multiple sources of bias confound functional enrichment analysis of global -omics data. *Genome Biol* 16, 186.
- Traynelis, S. F., Wollmuth, L. P., McBain, C. J., Menniti, F. S., Vance, K. M., Ogden, K. K., Hansen, K. B., Yuan, H., Myers, S. J. & Dingledine, R. 2010. Glutamate receptor ion channels: structure, regulation, and function. *Pharmacol Rev* 62, 405-96.
- Tsai, P.C. and Bell, J.T., 2015. Power and sample size estimation for epigenome-wide association scans to detect differential DNA methylation. *International journal of epidemiology*, 44(4), pp.1429-1441.

- Turecki, G. & Meaney, M. J. 2014. Effects of the Social Environment and Stress on Glucocorticoid Receptor Gene Methylation: A Systematic Review. *Biol Psychiatry*.
- Vaillant, G. E., Okereke, O. I., Mukamal, K. & Waldinger, R. J. 2014. Antecedents of intact cognition and dementia at age 90 years: a prospective study. *Int J Geriatr Psychiatry* 29, 1278-85.
- Vandewalle, J., Langen, M., Zschaetzsch, M., Nijhof, B., Kramer, J. M., Brems, H., Bauters, M., Lauwers, E., Srahna, M., Marynen, P., Verstreken, P., Schenck, A., Hassan, B. A. & Froyen, G. 2013. Ubiquitin Ligase HUWE1 Regulates Axon Branching through the Wnt/ β -Catenin Pathway in a *Drosophila* Model for Intellectual Disability. *PLoS ONE* 8, e81791.
- World Health Organization. 2014. Global status report on violence prevention 2014. Geneva: World Health Organization.
- Yamamoto, H., Hagino, Y., Kasai, S. & Ikeda, K. 2015. Specific Roles of NMDA Receptor Subunits in Mental Disorders. *Current Molecular Medicine* 15, 193-205.
- Yang, B.Z., Zhang, H., Ge, W., Weder, N., Douglas-Palumberi, H., Perepletchikova, F., Gelernter, J. and Kaufman, J. 2013. Child abuse and epigenetic mechanisms of disease risk. *American journal of preventive medicine*, 44(2),101-107.

Figure legends:**Figure 1. Associations between DNA methylation and maltreatment types.**

(A) Manhattan plots for physical abuse, sexual abuse and physical neglect; (B) scatterplots of DMPs indicated in (A) for each maltreatment type; and (C) scatterplots of hyper- and hypo-methylated DMPs *across* maltreatment types. *N.b.* The dotted line represents FDR correction (i.e. DMPs above the line are significant at $q < 0.05$).

Figure 2. Unique vs shared enriched biological processes across maltreatment types.

Significantly enriched biological processes for genes uniquely associated with each maltreatment type (physical abuse [green], physical neglect [blue]) vs those shared across maltreatment types (red), based on GO analysis. GO analysis was not run independently for sexual abuse (SA) due to limited gene *n*. Circles represent GO terms that survive FDR correction. The X axis represents $-\log(10)$ p values. The opacity of the circles indicates level of significance (darker = more significant). The size of the circles indicates the percentage of genes in our results for a given pathway compared to the total number of genes in the same pathway (i.e. larger size = larger %; range = 6.51% - 100%). *Abbreviations:* PA, physical abuse; PN, physical neglect; SA, sexual abuse.

Table 1. Descriptives and correlations between study variables.

<i>Maltreatment type</i>	<i>M (SD)</i>	<i>% above threshold (n)</i>	<i>1</i>	<i>2</i>	<i>3</i>	<i>4</i>	<i>Sex</i>	<i>Age</i>	<i>Ethnicity^b</i>			
									<i>White</i>	<i>Black</i>	<i>Mixed</i>	<i>Asian</i>
1. Emotional abuse	10.06 (4.99)	50.8 (63)	–				.01	.17	-.13	.19*	-.07	.00
2. Physical abuse	7.82 (4.70)	33.1 (41)	.57***	–			.01	.09	-.16	.26**	-.08	-.06
3. Sexual abuse	6.14 (3.51)	17.0 (21)	.41***	.25***	–		.05	.13	-.11	.12	-.01	-.04
4. Emotional neglect	10.47 (4.81)	49.2 (61)	.73***	.55***	.35***	–	-.03	.18*	-.20*	.21*	-.09	.12
5. Physical neglect	7.55 (3.61)	32.3 (40)	.65***	.60***	.36***	.71***	-.07	.14	-.22*	.31***	-.11	.00

N.B. Intercorrelations between maltreatment types, and their association with socio-demographic characteristics (age, sex and ethnicity). A product-moment correlation is used for associations between two continuous variables, while a point-biserial correlation is used for associations between one continuous and one dichotomous variable (i.e. sex, ethnicity). Bivariate correlations significant at: * $p < .05$, ** $p < .01$, *** $p < .001$.

^a For descriptive purposes, this column shows the percentage of participants who scored above the ‘Low’ maltreatment threshold specified by the CTQ manual.

^b Each ethnic group coded as 1 = yes and 0 = no, based on self-reported ethnicity.

Table 2. Top 10 DMPs associated with physical abuse, sexual abuse and physical neglect.

CpG probe	Gene	Chr	Genomic location	Position	<i>B</i> diff. ^a	Std . <i>B</i> ^b	P-value	FDR (q)
A. Physical abuse (N FDR-corrected DMPs = 34)								
cg20000641	<i>PSEN2</i>	1	TSS1500	227058046	0.14	0.55	2.53E-11	1.47E-05
cg02353937	<i>SMC1A/RIBC1</i>	X	TSS1500	53449152	0.09	0.50	2.90E-09	7.89E-04
cg15440363	<i>GPD1L</i>	3	TSS200	32148023	0.05	0.48	2.06E-08	3.64E-03
cg04412054	<i>GALNS</i>	16	Body	88897539	-0.12	-0.46	5.69E-08	0.01
cg22311608	<i>SMC1A/RIBC1</i>	X	TSS200	53449829	0.09	0.46	8.45E-08	0.01
cg24365098	<i>C11orf84</i>	11	3'UTR	63594804	-0.12	-0.45	1.43E-07	0.01
cg03561071	<i>[FAT3]</i>	11	--	91844355	-0.11	-0.44	4.28E-07	0.03
cg26454299	<i>PPP3CA</i>	4	--	102268957	0.10	0.43	5.58E-07	0.03
cg25047485	<i>[ARHGAP39]</i>	8	--	145848944	-0.11	-0.43	8.14E-07	0.04
cg04524770	<i>LMF1</i>	16	Body	946408	-0.11	-0.42	9.96E-07	0.04
B. Sexual abuse (N FDR-corrected DMPs = 7)								
cg17106653	<i>GRIN2D</i>	19	TSS1500	48897279	0.22	0.50	4.16E-09	1.72E-03
cg00974464	<i>PRDM15</i>	21	Body	43254115	-0.12	-0.46	6.02E-08	0.01
cg26528551	<i>MGMT</i>	10	Body	131445415	-0.09	-0.46	6.84E-08	0.01
cg10795666	<i>MLNR</i>	13	1stExon	49794635	0.09	0.45	2.23E-07	0.02
cg02618355	<i>MYOM2</i>	8	Body	2024368	-0.09	-0.44	2.88E-07	0.02
cg26513050	<i>DIAPH2/RPA4</i>	X	Body	96138983	-0.18	-0.44	2.91E-07	0.02
cg23983710	<i>DIP2C</i>	10	Body	370756	-0.16	-0.43	5.83E-07	0.03
C. Physical neglect (N FDR-corrected DMPs = 118)								
cg00691266	<i>EVPL</i>	17	Body	74015089	-0.08	-0.46	1.01E-07	0.01
cg27083825	<i>SYNJ2</i>	6	Body	158453594	-0.07	-0.45	1.02E-07	0.01
cg17918089	<i>SETDB1</i>	1	Body	150899251	0.08	0.45	1.14E-07	0.01
cg10094509	<i>MAP2K4P1/CHIC1</i>	X	TSS1500	72783579	0.09	0.45	1.16E-07	0.01
cg09863040	<i>JADE1</i>	4	TSS200	129730729	0.02	0.44	2.10E-07	0.01
cg08796898	<i>HUWE1</i>	X	5'UTR	53713664	0.14	0.44	3.59E-07	0.02

cg20668974	<i>ZNF827</i>	4	Body	146857981	0.06	0.44	3.63E-07	0.02
cg18116160	<i>GABBR1</i>	6	Body	29575145	-0.04	-0.44	4.01E-07	0.02
cg09084892	<i>FAT1</i>	4	Body	187557837	-0.12	-0.43	4.35E-07	0.02
cg08054907	<i>HIST1H1A</i>	6	TSS1500	26019358	-0.09	-0.43	5.12E-07	0.02

N.B. Gene names in brackets indicate the most proximal genes to the CpG probe based on Genome Studio. Genes with multiple significant probes are highlighted in blue.

^a Beta differences indicate the overall difference (% methylation change) between the predicted unstandardized minimum and maximum values of the linear model.

^b Standardized Beta estimates are used as a measure of effect size, where an effect of 0.10 is small effect, an effect of 0.24 is a medium effect, and an effect of 0.37 is a large effect.

Table 3. Top 20 hyper- and hypo-methylated DMPs across maltreatment types (physical abuse, sexual abuse and neglect), ranked by average effect size.

CpG probe	Gene	Chr	Genomic location	Position	Physical Abuse		Sexual Abuse		Neglect		Average StdB
					StdB	p-value	StdB	p-value	StdB	p-value	
A. Hypermethylated											
cg08796898	HUWE1	X	5'UTR	53713664	0.38	1.10E-05	0.21	2.19E-02	0.44	3.83E-07	0.34
cg21239691	GEMIN8	X	TSS200	14048191	0.42	1.24E-06	0.18	4.38E-02	0.39	7.20E-06	0.33
cg04704856	FMOD	1	1stExon	203320190	0.32	2.46E-04	0.27	2.61E-03	0.37	2.36E-05	0.32
cg12986338	[PDE1C]	7	--	32338950	0.28	1.39E-03	0.31	4.15E-04	0.35	6.27E-05	0.32
cg23436576	TDH	8	Body	11204132	0.35	7.16E-05	0.23	8.75E-03	0.35	6.17E-05	0.31
cg25051341	PRDM13	6	Body	100061307	0.27	2.79E-03	0.28	1.40E-03	0.38	1.30E-05	0.31
cg19637330	[PAX7]	1	--	19110922	0.26	3.73E-03	0.31	4.51E-04	0.36	3.98E-05	0.31
cg26163537	GRB10	7	TSS1500	50861592	0.36	3.84E-05	0.19	3.76E-02	0.38	1.37E-05	0.31
cg25579180	WBSCR17	7	Body	71098623	0.36	4.53E-05	0.32	3.03E-04	0.25	5.24E-03	0.31
cg12627354	LRP4	11	TSS1500	46940434	0.26	3.29E-03	0.28	1.56E-03	0.38	1.67E-05	0.31
cg08121755	[KRT80]	12	--	52545978	0.27	2.15E-03	0.34	1.39E-04	0.29	9.09E-04	0.30
cg03309770	TVP23A	16	1stExon	10912478	0.38	1.17E-05	0.21	1.66E-02	0.30	6.53E-04	0.30
cg21453209	[ZFAND1]	8	--	82635831	0.32	3.47E-04	0.25	5.99E-03	0.33	2.23E-04	0.30
cg20594607	LOC338799	12	TSS200	122241438	0.33	1.94E-04	0.24	7.13E-03	0.31	3.81E-04	0.29
cg26840590	PHF1	6	5'UTR	33379330	0.32	2.86E-04	0.22	1.23E-02	0.34	1.39E-04	0.29
cg04530860	B9D2	19	TSS200	41870213	0.38	1.69E-05	0.24	7.20E-03	0.26	3.45E-03	0.29
cg17962547	GPR123	10	Body	134918974	0.32	3.57E-04	0.25	5.39E-03	0.31	4.39E-04	0.29
cg11480019	ADK	10	--	75936982	0.30	8.66E-04	0.32	3.13E-04	0.25	4.48E-03	0.29
cg09387749	HOXD3	2	TSS200	177028680	0.31	5.34E-04	0.24	7.14E-03	0.32	3.50E-04	0.29
cg27516159	CACNA2D4	12	Body	1904847	0.28	1.81E-03	0.22	1.27E-02	0.35	6.03E-05	0.28

B. Hypomethylated											
cg10494397	<i>CC2D2A</i>	4	Body	15593854	-0.39	7.89E-06	-0.24	6.61E-03	-0.42	1.35E-06	-0.35
cg27496299	<i>DNAJB6</i>	7	Body	157171202	-0.38	1.56E-05	-0.28	1.84E-03	-0.39	6.90E-06	-0.35
cg27632471	<i>C20orf96</i>	20	Body	259123	-0.27	2.41E-03	-0.39	8.78E-06	-0.39	9.42E-06	-0.35
cg07870603	<i>RPTOR</i>	17	Body	78880144	-0.28	1.37E-03	-0.38	1.43E-05	-0.33	2.28E-04	-0.33
cg09596252	<i>RPTOR</i>	17	Body	78655493	-0.41	3.00E-06	-0.28	1.62E-03	-0.30	7.06E-04	-0.33
cg01786585	<i>TIAM2</i>	6	--	155315188	-0.37	2.00E-05	-0.35	8.70E-05	-0.26	3.59E-03	-0.33
cg23523534	<i>NLRP11</i>	19	5'UTR	56347927	-0.33	1.45E-04	-0.32	3.12E-04	-0.32	3.59E-04	-0.32
cg16560389	<i>[TCERG1L]</i>	10	--	133318201	-0.34	9.50E-05	-0.22	1.32E-02	-0.40	3.60E-06	-0.32
cg05157878	<i>GCNT2</i>	6	--	10494860	-0.29	1.05E-03	-0.38	1.57E-05	-0.29	1.30E-03	-0.32
cg21473728	<i>MYOM2</i>	8	Body	2031651	-0.36	4.62E-05	-0.20	2.57E-02	-0.39	7.42E-06	-0.32
cg21385432	<i>EP400</i>	12	Body	132512858	-0.31	4.33E-04	-0.24	6.55E-03	-0.39	7.04E-06	-0.32
cg19279265	<i>ACOX3</i>	4	Body	8388670	-0.27	2.83E-03	-0.41	1.73E-06	-0.26	3.66E-03	-0.31
cg03561071	<i>[FAT3]</i>	11	--	91844355	-0.44	4.28E-07	-0.22	1.35E-02	-0.28	1.99E-03	-0.31
cg22896075	<i>GJD3</i>	17	1stExon	38518413	-0.40	5.30E-06	-0.21	2.04E-02	-0.32	3.09E-04	-0.31
cg13521944	<i>C22orf9</i>	22	Body	45596948	-0.27	2.45E-03	-0.28	1.69E-03	-0.37	2.97E-05	-0.30
cg11650926	<i>[KIAA0947]</i>	5	--	5568539	-0.30	8.71E-04	-0.19	3.40E-02	-0.43	6.91E-07	-0.30
cg21076890	<i>COL4A2</i>	13	Body	110965662	-0.30	8.61E-04	-0.19	3.93E-02	-0.43	5.51E-07	-0.30
cg03500617	<i>[FA2H]</i>	16	--	74812570	-0.31	4.27E-04	-0.19	3.11E-02	-0.41	2.86E-06	-0.30
cg02866700	<i>CARS2</i>	13	Body	111333333	-0.30	7.85E-04	-0.26	3.98E-03	-0.35	5.79E-05	-0.30
cg13920529	<i>SUGTIP1</i>	9	Body	33402426	-0.34	9.08E-05	-0.21	1.85E-02	-0.35	6.28E-05	-0.30

N.B. Gene names in brackets indicate the most proximal genes to the CpG probe based on Genome Studio. Genes with multiple significant probes are highlighted in blue.

Figure 1.

Figure 2.

Supplementary Information

Epigenetic signatures of childhood abuse and neglect: Implications for psychiatric

List of supplementary materials:

- OS1.** Optimized gene ontology (GO) method.
- OS2.** Top 10 DMPs associated with emotional abuse and emotional neglect.
- OS3.** Full list of FDR-corrected loci associated with physical abuse, sexual abuse and physical neglect.
- OS4.** Quantile-quantile plots for each maltreatment type.
- OS5.** Sensitivity analyses for FDR-corrected DMPs associated with physical abuse, sexual abuse and physical neglect.
- OS6.** Enriched biological processes for genes associated with epigenetic variation that is unique to physical abuse and physical neglect.
- OS7.** Enriched biological processes for genes associated with epigenetic variation that is shared across maltreatment types (physical abuse, sexual abuse and physical neglect).

OS1. Optimized gene ontology (GO) method

A logistic regression approach was used to test if genes in the test list predicted pathway membership while controlling for the number probes annotated to each gene. Pathways were downloaded from the Gene Ontology website and all genes annotated to parent terms were also included. Illumina UCSC gene annotation was used to create a test gene list from probes that shown unique vs shared associations with maltreatment, depending on the analysis performed. All genes with at least one methylation probe annotated and annotated to at least one GO pathway were considered. Pathways were filtered to those with between 10 and 2000 genes in. After applying this method to all pathways, significant pathways ($p < 0.05$) were taken and grouped where overlapping genes explained the signal. This was achieved by taking the most significant pathway, and retesting all remaining significant pathways while controlling additionally for the best term. If genes in the test list no longer predicted the pathway, the term was said to be explained by the most significant pathway, and hence these pathways were grouped together. This algorithm was repeated, taking the next most significant term, until all pathways had been considered as the most significant or found to be explained by a more significant term. GO terms were interpreted exclusively if they if they contained more than 1 gene and passed FDR-correction, based on the final list of independent (non-redundant) terms.

OS2. Top 10 DMPs associated with emotional abuse and emotional neglect

CpG probe	Gene	Chr	Genomic location	Position	Std .B	P-value	FDR (q)
A. Emotional abuse							
cg23436576	<i>TDH</i>	8	Body	11204132	0.38	1.17E-05	1.00
cg10933494	<i>[ZNF311]</i>	6	--	28983143	-0.38	1.56E-05	1.00
cg00742603	<i>DBNDD1</i>	16	TSS1500	90086301	0.37	1.89E-05	1.00
cg00347856	<i>[FLJ45974]</i>	7	--	53879253	-0.37	1.95E-05	1.00
cg18116160	<i>GABBR1</i>	6	Body	29575145	-0.37	2.48E-05	1.00
cg11496014	<i>[BUB3]</i>	10	--	125115762	-0.36	3.43E-05	1.00
cg00436603	<i>CYP2E1</i>	10	TSS200	135340740	0.36	3.87E-05	1.00
cg13778848	<i>LOC283050</i>	10	Body	80746999	-0.35	6.40E-05	1.00
cg04477202	<i>SPAST</i>	2	Body	32289458	0.35	7.76E-05	1.00
cg01067603	<i>DAB1</i>	1	5'UTR	58331989	-0.35	7.78E-05	1.00
B. Emotional neglect							
cg21964928	<i>[SAP30L]</i>	5	--	153872958	0.38	1.62E-05	1.00
cg19050351	<i>IL1F5</i>	2	Body	113820090	-0.37	2.48E-05	1.00
cg01630869	<i>CDC42EP2</i>	11	--	65082120	0.36	3.18E-05	1.00
cg10933494	<i>[ZNF311]</i>	6	--	28983143	-0.36	3.31E-05	1.00
cg07603484	<i>NUP62</i>	19	TSS1500	50434179	-0.35	5.99E-05	1.00
cg18994566	<i>ZFYVE21</i>	14	Body	104191347	-0.35	6.71E-05	1.00
cg13161621	<i>IQSEC2</i>	X	Body	53348705	0.35	6.81E-05	1.00
cg13688202	<i>SPTB</i>	14	Body	65230287	-0.35	8.06E-05	1.00
cg09796576	<i>ZNF526</i>	19	Body	42729528	-0.35	8.28E-05	1.00
cg18852899	<i>RMDN2</i>	2	--	38154797	-0.35	8.33E-05	1.00

N.B. Gene names in brackets indicate the most proximal genes to the CpG probe based on Genome Studio. Standardized Beta estimates are used as a measure of effect size, where an effect of 0.10 is small effect, an effect of 0.24 is a medium effect, and an effect of 0.37 is a large effect.

OS3. Full list of FDR-corrected DMPs associated with physical abuse, sexual abuse and physical neglect

CpG probe	Gene	Chr	Genomic location	Position	Std .B	P-value	FDR (q)
A. Physical abuse (FDR_n = 34)							
cg20000641	<i>PSEN2</i>	1	TSS1500	227058046	0.55	2.53E-11	1.47E-05
cg02353937	<i>SMCIA/RIBC1</i>	X	TSS1500	53449152	0.50	2.90E-09	7.89E-04
cg15440363	<i>GPD1L</i>	3	TSS200	32148023	0.48	2.06E-08	3.64E-03
cg04412054	<i>GALNS</i>	16	Body	88897539	-0.46	5.69E-08	0.01
cg22311608	<i>SMCIA/RIBC1</i>	X	TSS200	53449829	0.46	8.45E-08	0.01
cg24365098	<i>C11orf84</i>	11	3'UTR	63594804	-0.45	1.43E-07	0.01
cg03561071	--	11	--	91844355	-0.44	4.28E-07	0.03
cg26454299	<i>PPP3CA</i>	4	--	102268957	0.43	5.58E-07	0.03
cg25047485	--	8	--	145848944	-0.43	8.14E-07	0.04
cg04524770	<i>LMF1</i>	16	Body	946408	-0.42	9.96E-07	0.04
cg16856833	--	3	--	87138640	0.42	1.01E-06	0.04
cg19736040	<i>SHC2</i>	19	Body	451261	-0.42	1.14E-06	0.04
cg21239691	<i>GEMIN8</i>	X	TSS200	14048191	0.42	1.24E-06	0.04
cg10390589	<i>SAE1</i>	19	TSS200	47634047	0.42	1.37E-06	0.04
cg04554728	--	1	--	150185568	-0.42	1.50E-06	0.04
cg16193029	<i>FBXW12</i>	3	TSS200	48413550	-0.42	1.60E-06	0.04
cg02350090	--	5	--	1951736	-0.41	1.70E-06	0.04
cg03013329	<i>IMPACT</i>	18	Body	22006989	0.41	1.74E-06	0.04
cg08879390	--	19	--	13979907	-0.41	1.80E-06	0.04
cg03402073	<i>PMM1</i>	22	Body	41974480	-0.41	1.95E-06	0.04
cg26151355	<i>KLHL6</i>	3	Body	183226025	-0.41	2.01E-06	0.04
cg10370025	<i>ABR</i>	17	--	926264	-0.41	2.12E-06	0.04
cg12710220	<i>PRKAG2</i>	7	Body	151423672	-0.41	2.23E-06	0.04
cg07486666	--	7	--	41170679	-0.41	2.47E-06	0.04
cg26005482	--	6	--	449134	-0.41	2.48E-06	0.04
cg19115205	<i>LOC340094</i>	5	--	5062128	-0.41	2.56E-06	0.04
cg16210526	<i>TTC40</i>	10	--	134663864	-0.41	2.81E-06	0.04
cg09596252	<i>RPTOR</i>	17	Body	78655493	-0.41	3.00E-06	0.04
cg20560091	<i>ITGA11</i>	15	Body	68624879	-0.40	3.16E-06	0.04
cg05795849	<i>ITPR1</i>	3	Body	4794082	0.40	3.37E-06	0.04
cg24399376	<i>LOC100133545</i>	11	Body	2005497	-0.40	3.47E-06	0.04
cg10471356	<i>ATP11A</i>	13	Body	113382760	-0.40	3.59E-06	0.04
cg23261530	<i>RPS6KA2</i>	6	Body	167017999	-0.40	3.61E-06	0.04
cg20770311	<i>SMPD1</i>	11	TSS1500	6411396	0.40	3.64E-06	0.04
B. Sexual abuse (FDR_n = 7)							
cg17106653	<i>GRIN2D</i>	19	TSS1500	48897279	0.50	4.16E-09	1.72E-03
cg00974464	<i>PRDM15</i>	21	Body	43254115	-0.46	6.02E-08	0.01
cg26528551	<i>MGMT</i>	10	Body	131445415	-0.46	6.84E-08	0.01
cg10795666	<i>MLNR</i>	13	1stExon	49794635	0.45	2.23E-07	0.02
cg02618355	<i>MYOM2</i>	8	Body	2024368	-0.44	2.88E-07	0.02
cg26513050	<i>DIAPH2/RPA4</i>	X	Body	96138983	-0.44	2.91E-07	0.02
cg23983710	<i>DIP2C</i>	10	Body	370756	-0.43	5.83E-07	0.03

C. Physical neglect (FDR _n = 118)							
cg00691266	<i>EVPL</i>	17	Body	74015089	-0.46	1.01E-07	0.01
cg27083825	<i>SYNJ2</i>	6	Body	158453594	-0.45	1.02E-07	0.01
cg17918089	<i>SETDB1</i>	1	Body	150899251	0.45	1.14E-07	0.01
cg10094509	<i>MAP2K4P1/CHIC1</i>	X	TSS1500	72783579	0.45	1.16E-07	0.01
cg09863040	<i>JADE1</i>	4	TSS200	129730729	0.44	2.10E-07	0.01
cg08796898	<i>HUWE1</i>	X	5'UTR	53713664	0.44	3.59E-07	0.02
cg20668974	<i>ZNF827</i>	4	Body	146857981	0.44	3.63E-07	0.02
cg18116160	<i>GABBR1</i>	6	Body	29575145	-0.44	4.01E-07	0.02
cg09084892	<i>FAT1</i>	4	Body	187557837	-0.43	4.35E-07	0.02
cg08054907	<i>HIST1H1A</i>	6	TSS1500	26019358	-0.43	5.12E-07	0.02
cg21076890	<i>COL4A2</i>	13	Body	110965662	-0.43	5.18E-07	0.02
cg17742334	--	1	--	9489130	0.43	5.31E-07	0.02
cg11650926	--	5	--	5568539	-0.43	6.50E-07	0.02
cg13409248	<i>ENTPD3</i>	3	TSS200	40428643	0.43	7.50E-07	0.02
cg09155575	<i>ORMDL3</i>	17	TSS200	38084037	0.43	8.07E-07	0.02
cg07728092	<i>EIF5A2</i>	3	TSS1500	170626980	-0.42	8.55E-07	0.02
cg18458353	<i>CEACAM5</i>	19	TSS1500	42211171	0.42	8.89E-07	0.02
cg21845580	<i>SPRYD3</i>	12	Body	53472882	0.42	9.37E-07	0.02
cg21634218	<i>FLJ26850</i>	19	TSS1500	50553699	0.42	1.01E-06	0.02
cg17693420	<i>ZNF655</i>	7	5'UTR	99157059	0.42	1.06E-06	0.02
cg04480325	--	2	--	37422917	-0.42	1.09E-06	0.02
cg06779606	<i>CARD11</i>	7	5'UTR	3041079	-0.42	1.14E-06	0.02
cg10494397	<i>CC2D2A</i>	4	Body	15593854	-0.42	1.28E-06	0.02
cg00311772	<i>PPP1R7</i>	2	Body	242092919	-0.42	1.32E-06	0.02
cg26248645	<i>PELI1</i>	2	5'UTR	64370690	0.42	1.36E-06	0.02
cg18001780	--	11	--	128500564	0.42	1.48E-06	0.02
cg18022926	<i>PBLD/HNRNPH3</i>	10	TSS1500	70093071	0.42	1.54E-06	0.02
cg02550027	<i>BLOC1S2</i>	10	TSS1500	102046474	0.41	1.64E-06	0.02
cg17309464	<i>ZNF565</i>	19	5'UTR	36705192	0.41	1.96E-06	0.02
cg04586332	--	22	--	45659810	0.41	2.00E-06	0.02
cg07032930	<i>MRPL53</i>	2	3'UTR	74699212	0.41	2.16E-06	0.03
cg02430183	<i>WNK2</i>	9	1stExon	95947766	-0.41	2.17E-06	0.03
cg06850509	--	2	--	96314847	-0.41	2.22E-06	0.03
cg24114390	<i>FAM133A</i>	X	TSS1500	92928730	0.41	2.32E-06	0.03
cg17822007	--	3	--	155463780	0.41	2.37E-06	0.03
cg14030997	--	9	--	108420639	-0.41	2.49E-06	0.03
cg14679558	--	13	--	21652153	-0.41	2.70E-06	0.03
cg12637205	<i>CYLD</i>	16	5'UTR	50776628	0.41	2.71E-06	0.03
cg09090582	<i>CNPY1</i>	7	5'UTR	155324691	0.41	2.77E-06	0.03
cg03500617	--	16	--	74812570	-0.41	2.86E-06	0.03
cg10493855	<i>TTC7B</i>	14	Body	91087586	-0.41	2.89E-06	0.03
cg14945917	--	4	--	38145641	-0.41	2.95E-06	0.03
cg16539640	<i>CYFIP1</i>	15	Body	22945028	-0.41	2.98E-06	0.03
cg02564272	<i>MAN1A1</i>	6	Body	119507963	-0.41	3.04E-06	0.03
cg18073471	<i>PRDM8</i>	4	5'UTR	81119198	0.40	3.24E-06	0.03
cg27568885	<i>GCNT3</i>	15	Body	59911449	-0.40	3.45E-06	0.03
cg13468418	--	4	--	186048907	0.40	3.54E-06	0.03
cg16560389	--	10	--	133318201	-0.40	3.60E-06	0.03

cg16210526	--	10	--	134663864	-0.40	3.71E-06	0.03
cg13521097	<i>FERMT2</i>	14	5'UTR	53417433	0.40	3.85E-06	0.03
cg15799267	<i>ALOX15B</i>	17	5'UTR	7942406	0.40	4.08E-06	0.03
cg19270277	<i>CROCC</i>	1	Body	17296995	-0.40	4.10E-06	0.03
cg04375213	<i>DCPIB</i>	12	Body	2113435	0.40	4.12E-06	0.03
cg13109184	<i>LYST</i>	1	--	236029439	0.40	4.40E-06	0.03
cg22902505	<i>PRDM8</i>	4	5'UTR	81119473	0.40	4.79E-06	0.04
cg08614562	<i>KIF1A</i>	2	Body	241665572	-0.40	5.13E-06	0.04
cg19864758	<i>PCSK2</i>	20	TSS1500	17206720	0.40	5.19E-06	0.04
cg27063720	<i>EP400NL</i>	12	Body	132568987	0.40	5.23E-06	0.04
cg24604043	<i>SLC39A3</i>	19	TSS1500	2740392	0.40	5.34E-06	0.04
cg15136913	--	10	--	134893540	-0.40	5.38E-06	0.04
cg19091677	<i>HMGB2</i>	4	TSS1500	174255518	0.40	5.44E-06	0.04
cg10625723	--	4	--	6235503	-0.40	5.50E-06	0.04
cg07821496	<i>TDRKH</i>	1	5'UTR	151762942	0.40	5.51E-06	0.04
cg08294772	--	8	--	138135392	0.40	5.52E-06	0.04
cg26309691	<i>SCCPDH</i>	1	Body	246887944	0.39	6.14E-06	0.04
cg21074877	--	14	--	23481968	-0.39	6.54E-06	0.04
cg19827167	<i>MIR760</i>	1	TSS200	94312206	0.39	6.56E-06	0.04
cg27330720	<i>FBXL20</i>	17	TSS1500	37558981	0.39	6.67E-06	0.04
cg05130304	<i>C3orf23</i>	3	TSS1500	44379503	0.39	6.72E-06	0.04
cg26509269	--	17	--	34970306	-0.39	6.89E-06	0.04
cg27496299	<i>DNAJB6</i>	7	Body	157171202	-0.39	6.90E-06	0.04
cg02458885	<i>PRDM8</i>	4	5'UTR	81119249	0.39	6.93E-06	0.04
cg21385432	<i>EP400</i>	12	Body	132512858	-0.39	7.04E-06	0.04
cg06874656	<i>NTM</i>	11	TSS1500	131780353	0.39	7.10E-06	0.04
cg21239691	<i>GEMIN8</i>	X	TSS200	14048191	0.39	7.20E-06	0.04
cg00895834	<i>PRDM16</i>	1	Body	3147966	-0.39	7.20E-06	0.04
cg21473728	<i>MYOM2</i>	8	Body	2031651	-0.39	7.42E-06	0.04
cg10390589	<i>SAE1</i>	19	TSS200	47634047	0.39	7.64E-06	0.04
cg10246772	<i>IGFIR</i>	15	Body	99250916	-0.39	7.90E-06	0.04
cg02514021	<i>FLJ43663</i>	7	Body	130791171	0.39	8.24E-06	0.04
cg10609984	<i>ZNF25</i>	10	TSS200	38265593	0.39	8.43E-06	0.04
cg25087154	<i>ILIRAP</i>	3	TSS1500	190231338	0.39	8.47E-06	0.04
ch.11.150171F	<i>NUP98</i>	11	Body	3739920	0.39	9.00E-06	0.04
cg23284284	<i>GIGYF2</i>	2	TSS200	233561917	0.39	9.02E-06	0.04
cg01093285	<i>PTPRN2</i>	7	Body	157436506	-0.39	9.38E-06	0.04
cg27632471	<i>C20orf96</i>	20	Body	259123	-0.39	9.42E-06	0.04
cg12411309	<i>SMUG1</i>	12	5'UTR	54582659	0.39	9.51E-06	0.04
cg17341361	<i>TNRC18</i>	7	Body	5414170	-0.39	9.51E-06	0.04
cg07124687	--	6	--	28956332	0.39	9.71E-06	0.04
cg12154976	<i>RASGEF1C</i>	5	5'UTR	179585198	-0.39	9.84E-06	0.04
cg12398448	<i>IGFIR</i>	15	Body	99251461	-0.39	9.87E-06	0.04
cg10462751	<i>RIC8B</i>	12	TSS200	107168330	0.38	1.03E-05	0.05
cg04204072	<i>THUMPDI</i>	16	1stExon	20752857	0.38	1.04E-05	0.05
cg10962490	<i>GLIS1</i>	1	5'UTR	54072456	-0.38	1.05E-05	0.05
cg13653274	--	10	--	132632928	-0.38	1.07E-05	0.05
cg15472403	<i>OSCAR</i>	19	Body	54599455	0.38	1.09E-05	0.05
cg00014152	<i>WDR13</i>	X	Body	48457128	-0.38	1.10E-05	0.05

cg25247351	<i>HLA-DMB</i>	6	1stExon	32908794	0.38	1.11E-05	0.05
cg03156396	<i>MSLN</i>	16	Body	816177	-0.38	1.13E-05	0.05
cg10650870	<i>TNPO1</i>	5	Body	72144764	0.38	1.15E-05	0.05
cg01487433	<i>CILP2</i>	19	TSS200	19648987	-0.38	1.15E-05	0.05
cg22533689	<i>EPHA2</i>	1	Body	16464479	-0.38	1.16E-05	0.05
cg13735965	<i>ZNF616</i>	19	TSS1500	52643487	0.38	1.18E-05	0.05
cg07307426	<i>DET1</i>	15	5'UTR	89089587	0.38	1.18E-05	0.05
cg25002318	<i>TRPV1</i>	17	Body	3471868	-0.38	1.20E-05	0.05
cg19554389	<i>WNT5A</i>	3	1stExon	55521134	0.38	1.20E-05	0.05
cg16953816	<i>VPS37B</i>	12	3'UTR	123349952	-0.38	1.22E-05	0.05
cg14604000	<i>C5orf13</i>	5	TSS1500	111093875	0.38	1.24E-05	0.05
cg11969467	<i>MRPS14</i>	1	TSS200	174992598	0.38	1.24E-05	0.05
cg03998119	<i>PTPN21</i>	14	Body	88945315	-0.38	1.25E-05	0.05
cg03041046	<i>SPRYD3</i>	12	5'UTR	53473136	0.38	1.27E-05	0.05
cg25051341	<i>PRDM13</i>	6	Body	100061307	0.38	1.30E-05	0.05
cg01407073	<i>NAP1L1</i>	12	TSS200	76478898	0.38	1.30E-05	0.05
cg15874300	<i>CRBN</i>	3	Body	3221199	0.38	1.31E-05	0.05
cg13144843	--	3	--	174158740	0.38	1.33E-05	0.05
cg26163537	<i>GRB10</i>	7	TSS1500	50861592	0.38	1.37E-05	0.05
cg20657691	<i>RBM3</i>	X	TSS1500	48432562	0.38	1.38E-05	0.05
cg06616055	<i>MUPCDH</i>	11	Body	623756	0.38	1.42E-05	0.05

N.B. Genes with multiple significant probes are highlighted in blue. Standardized Beta estimates are used as a measure of effect size, where an effect of 0.10 is small effect, an effect of 0.24 is a medium effect, and an effect of 0.37 is a large effect.

OS4. Quantile-quantile plots for each maltreatment type

A. Physical abuse

B. Sexual abuse

C. Physical neglect

D. Emotional abuse

E. Emotional neglect

OS5: Sensitivity analyses for FDR-corrected DMPs associated with physical abuse, sexual abuse and physical neglect

CpG probe	Gene	Chr	Genomic location	Position	Sensitivity Analyses									High confidence association ^e
					Original analysis ^a		SVA analysis ^b		Winsorized analysis ^c		Bootstrapping ^d			
					<i>p</i> -value	<i>q</i> -value	<i>p</i> -value	<i>q</i> -value	<i>p</i> -value	<i>q</i> -value	<i>B</i>	95% CI		
A. Physical abuse (<i>n</i> = 34)														
cg20000641	<i>PSEN2</i>	1	TSS1500	227058046	2.53E-11	1.47E-05	4.205E-09	4.91E-04	1.64E-03	0.61	-0.006	-0.010	-0.001	*
cg02353937	<i>SMCIA/RIBC1</i>	X	TSS1500	53449152	2.90E-09	7.89E-04	1.922E-08	1.35E-03	1.26E-04	0.42	-0.006	-0.012	-0.001	*
cg15440363	<i>GPDIL</i>	3	TSS200	32148023	2.06E-08	3.64E-03	3.819E-09	4.91E-04	0.05	0.76	-0.005	-0.009	-0.001	*
cg04412054	<i>GALNS</i>	16	Body	88897539	5.69E-08	0.01	1.244E-05	0.04	0.01	0.69	-0.005	-0.010	-0.001	*
cg22311608	<i>SMCIA/RIBC1</i>	X	TSS200	53449829	8.45E-08	0.01	1.486E-05	0.04	1.50E-05	0.22	-0.006	-0.011	-0.001	*
cg24365098	<i>C11orf84</i>	11	3'UTR	63594804	1.43E-07	0.01	8.455E-05	0.07	9.76E-03	0.69	-0.009	-0.014	-0.003	-
cg03561071	<i>[FAT3]</i>	11	--	91844355	4.28E-07	0.03	1.174E-06	0.01	7.25E-04	0.58	-0.004	-0.006	-0.001	*
cg26454299	<i>PPP3CA</i>	4	--	102268957	5.58E-07	0.03	1.073E-05	0.04	9.16E-04	0.59	-0.006	-0.010	-0.001	*
cg25047485	<i>[ARHGAP39]</i>	8	--	145848944	8.14E-07	0.04	1.857E-05	0.04	0.01	0.69	-0.004	-0.006	-0.003	*
cg04524770	<i>LMF1</i>	16	Body	946408	9.96E-07	0.04	1.270E-06	0.01	0.02	0.72	-0.012	-0.020	-0.004	*
cg16856833	<i>[VGLL3]</i>	3	--	87138640	1.01E-06	0.04	1.605E-05	0.04	1.29E-03	0.60	-0.006	-0.011	-0.001	*
cg19736040	<i>SHC2</i>	19	Body	451261	1.14E-06	0.04	8.149E-06	0.03	3.69E-03	0.64	-0.003	-0.005	-0.001	*
cg21239691	<i>GEMIN8</i>	X	TSS200	14048191	1.24E-06	0.04	8.405E-04	0.15	1.22E-05	0.22	-0.004	-0.006	-0.001	-
cg10390589	<i>SAE1</i>	19	TSS200	47634047	1.37E-06	0.04	1.177E-06	0.01	4.86E-03	0.65	-0.003	-0.006	0.000	-
cg04554728	<i>[ANP32E]</i>	1	--	150185568	1.50E-06	0.04	5.394E-07	0.01	1.08E-03	0.60	-0.008	-0.016	-0.002	*
cg16193029	<i>FBXW12</i>	3	TSS200	48413550	1.60E-06	0.04	8.757E-06	0.04	0.48	0.90	-0.012	-0.022	-0.004	-
cg02350090	<i>[IRX4]</i>	5	--	1951736	1.70E-06	0.04	5.984E-05	0.06	2.04E-06	0.19	-0.006	-0.010	-0.002	-
cg03013329	<i>IMPACT</i>	18	Body	22006989	1.74E-06	0.04	4.188E-04	0.13	9.24E-03	0.68	-0.003	-0.005	-0.002	-
cg08879390	<i>[NANOS3]</i>	19	--	13979907	1.80E-06	0.04	6.189E-06	0.03	1.47E-03	0.61	-0.003	-0.005	-0.001	*
cg03402073	<i>PMM1</i>	22	Body	41974480	1.95E-06	0.04	2.855E-05	0.05	7.61E-03	0.67	-0.004	-0.008	-0.001	*
cg26151355	<i>KLHL6</i>	3	Body	183226025	2.01E-06	0.04	1.771E-04	0.10	6.15E-03	0.67	-0.003	-0.006	-0.001	-
cg10370025	<i>ABR</i>	17	--	926264	2.12E-06	0.04	1.124E-05	0.04	3.74E-03	0.64	-0.002	-0.003	0.000	-
cg12710220	<i>PRKAG2</i>	7	Body	151423672	2.23E-06	0.04	7.008E-06	0.03	7.05E-03	0.67	-0.003	-0.005	-0.002	*
cg07486666	<i>[C7orf10]</i>	7	--	41170679	2.47E-06	0.04	2.865E-05	0.05	0.02	0.73	0.002	0.000	0.003	-
cg26005482	<i>[IRF4]</i>	6	--	449134	2.48E-06	0.04	4.799E-05	0.06	2.32E-03	0.63	0.006	0.002	0.011	-

cg19115205	<i>LOC340094</i>	5	--	5062128	2.56E-06	0.04	7.828E-06	0.03	6.99E-05	0.40	0.005	0.001	0.009	*
cg16210526	<i>TTC40</i>	10	--	134663864	2.81E-06	0.04	8.721E-07	0.01	1.01E-05	0.22	0.002	0.000	0.004	-
cg09596252	<i>RPTOR</i>	17	Body	78655493	3.00E-06	0.04	6.730E-05	0.07	2.63E-04	0.47	0.005	0.002	0.008	-
cg20560091	<i>ITGA11</i>	15	Body	68624879	3.16E-06	0.04	2.024E-05	0.05	2.35E-04	0.47	0.004	0.001	0.007	*
cg05795849	<i>ITPR1</i>	3	Body	4794082	3.37E-06	0.04	3.684E-08	1.84E-03	3.42E-04	0.51	0.005	0.001	0.008	*
cg24399376	<i>LOC100133545</i>	11	Body	2005497	3.47E-06	0.04	5.354E-05	0.06	1.38E-03	0.61	0.004	0.002	0.007	-
cg10471356	<i>ATP11A</i>	13	Body	113382760	3.59E-06	0.04	4.097E-05	0.05	1.53E-03	0.61	0.003	0.000	0.005	-
cg23261530	<i>RPS6KA2</i>	6	Body	167017999	3.61E-06	0.04	3.408E-05	0.05	4.74E-05	0.37	0.004	0.002	0.007	*
cg20770311	<i>SMPD1</i>	11	TSS1500	6411396	3.64E-06	0.04	1.204E-06	0.01	2.48E-03	0.63	0.007	0.002	0.012	*

B. Sexual abuse (n = 7)

cg17106653	<i>GRIN2D</i>	19	TSS1500	48897279	4.16E-09	1.72E-03	8.46E-10	1.75E-04	0.03	1.00	0.011	-0.001	0.020	-
cg00974464	<i>PRDM15</i>	21	Body	43254115	6.02E-08	0.01	3.21E-09	3.32E-04	0.15	1.00	-0.006	-0.012	0.000	-
cg26528551	<i>MGMT</i>	10	Body	131445415	6.84E-08	0.01	2.66E-09	3.32E-04	0.04	1.00	-0.005	-0.010	0.000	-
cg10795666	<i>MLNR</i>	13	1stExon	49794635	2.23E-07	0.02	1.21E-07	3.85E-03	1.90E-05	1.00	0.005	0.002	0.009	*
cg02618355	<i>MYOM2</i>	8	Body	2024368	2.88E-07	0.02	3.58E-08	1.85E-03	0.03	1.00	-0.004	-0.011	0.000	-
cg26513050	<i>DIAPH2/RPA4</i>	X	Body	96138983	2.91E-07	0.02	1.00E-07	3.46E-03	0.30	1.00	-0.009	-0.024	0.001	-
cg23983710	<i>DIP2C</i>	10	Body	370756	5.83E-07	0.03	2.32E-11	9.59E-06	0.05	1.00	-0.008	-0.013	0.000	-

C. Physical neglect (n = 118)

cg00691266	<i>EVPL</i>	17	Body	74015089	1.01E-07	0.01	3.27E-04	0.19	2.75E-05	0.13	-0.005	-0.007	-0.003	-
cg27083825	<i>SYNJ2</i>	6	Body	158453594	1.02E-07	0.01	1.39E-03	0.28	2.50E-04	0.15	-0.005	-0.008	-0.002	-
cg17918089	<i>SETDB1</i>	1	Body	150899251	1.14E-07	0.01	2.80E-09	1.04E-03	3.14E-03	0.19	0.005	0.001	0.009	*
cg10094509	<i>MAP2K4P1/CHIC1</i>	X	TSS1500	72783579	1.16E-07	0.01	3.82E-05	0.10	6.72E-06	0.12	0.006	0.001	0.011	-
cg09863040	<i>JADE1</i>	4	TSS200	129730729	2.10E-07	0.01	6.01E-07	0.02	7.85E-06	0.12	0.001	0	0.001	-
cg08796898	<i>HUWE1</i>	X	5'UTR	53713664	3.59E-07	0.02	2.48E-04	0.18	2.23E-05	0.13	0.01	0.005	0.014	-
cg20668974	<i>ZNF827</i>	4	Body	146857981	3.63E-07	0.02	2.13E-06	0.04	4.10E-05	0.13	0.004	0.002	0.006	*
cg18116160	<i>GABBR1</i>	6	Body	29575145	4.01E-07	0.02	8.27E-05	0.13	3.07E-06	0.11	-0.002	-0.004	-0.001	-
cg09084892	<i>FAT1</i>	4	Body	187557837	4.35E-07	0.02	4.65E-05	0.11	0.01	0.23	-0.008	-0.013	-0.002	-
cg08054907	<i>HIST1H1A</i>	6	TSS1500	26019358	5.12E-07	0.02	3.85E-05	0.10	1.13E-04	0.14	-0.006	-0.01	-0.002	-
cg21076890	<i>COL4A2</i>	13	Body	110965662	5.18E-07	0.02	1.09E-03	0.26	4.96E-04	0.16	-0.006	-0.01	-0.002	-
cg17742334	<i>[SLC25A33]</i>	1	--	9489130	5.31E-07	0.02	1.56E-04	0.15	1.27E-04	0.14	0.003	0.001	0.006	-
cg11650926	<i>[ADAMTS16]</i>	5	--	5568539	6.50E-07	0.02	1.13E-03	0.26	1.71E-03	0.17	-0.003	-0.006	-0.001	-

cg13409248	<i>ENTPD3</i>	3	TSS200	40428643	7.50E-07	0.02	9.30E-05	0.13	1.34E-04	0.14	0.002	0.001	0.003	-
cg09155575	<i>ORMDL3</i>	17	TSS200	38084037	8.07E-07	0.02	1.67E-07	0.02	0.09	0.35	0.005	0.001	0.01	-
cg07728092	<i>EIF5A2</i>	3	TSS1500	170626980	8.55E-07	0.02	1.80E-04	0.16	6.75E-05	0.13	-0.002	-0.004	-0.001	-
cg18458353	<i>CEACAM5</i>	19	TSS1500	42211171	8.89E-07	0.02	1.32E-06	0.04	1.57E-06	0.10	0.008	0.005	0.011	*
cg21845580	<i>SPRYD3</i>	12	Body	53472882	9.37E-07	0.02	5.37E-06	0.05	4.57E-06	0.12	0.005	0.003	0.007	*
cg21634218	<i>FLJ26850</i>	19	TSS1500	50553699	1.01E-06	0.02	4.31E-03	0.35	6.95E-04	0.16	0.011	0.005	0.018	-
cg17693420	<i>ZNF655</i>	7	5'UTR	99157059	1.06E-06	0.02	6.95E-04	0.23	3.69E-03	0.19	0.006	0.002	0.009	-
cg04480325	<i>[SULT6B1]</i>	2	--	37422917	1.09E-06	0.02	6.15E-03	0.38	8.24E-05	0.13	-0.006	-0.012	-0.003	-
cg06779606	<i>CARD11</i>	7	5'UTR	3041079	1.14E-06	0.02	1.59E-04	0.15	4.03E-05	0.13	-0.006	-0.008	-0.003	-
cg10494397	<i>CC2D2A</i>	4	Body	15593854	1.28E-06	0.02	5.73E-03	0.37	1.70E-03	0.17	-0.002	-0.005	-0.001	-
cg00311772	<i>PPP1R7</i>	2	Body	242092919	1.32E-06	0.02	9.47E-06	0.07	7.11E-06	0.12	-0.006	-0.009	-0.003	-
cg26248645	<i>PELI1</i>	2	5'UTR	64370690	1.36E-06	0.02	3.21E-06	0.05	5.00E-04	0.16	0.006	0.001	0.012	*
cg18001780	<i>[ETS1]</i>	11	--	128500564	1.48E-06	0.02	3.98E-05	0.11	2.41E-04	0.15	0.005	0.002	0.007	-
cg18022926	<i>PBLD/HNRNPH3</i>	10	TSS1500	70093071	1.54E-06	0.02	5.38E-06	0.05	0.05	0.31	0.005	0.001	0.011	*
cg02550027	<i>BLOC1S2</i>	10	TSS1500	102046474	1.64E-06	0.02	2.17E-03	0.30	2.38E-05	0.13	0.001	0.001	0.002	-
cg17309464	<i>ZNF565</i>	19	5'UTR	36705192	1.96E-06	0.02	2.67E-07	0.02	7.98E-03	0.21	0.004	0.001	0.008	*
cg04586332	<i>[UPK3A]</i>	22	--	45659810	2.00E-06	0.02	5.60E-05	0.11	2.58E-04	0.15	0.006	0.001	0.012	-
cg07032930	<i>MRPL53</i>	2	3'UTR	74699212	2.16E-06	0.03	1.38E-04	0.15	2.90E-05	0.13	0.002	0.001	0.003	-
cg02430183	<i>WNK2</i>	9	1stExon	95947766	2.17E-06	0.03	2.84E-04	0.18	0.01	0.22	-0.004	-0.007	0	-
cg06850509	--	2	--	96314847	2.22E-06	0.03	7.97E-03	0.40	3.15E-05	0.13	-0.005	-0.008	-0.003	-
cg24114390	<i>FAM133A</i>	X	TSS1500	92928730	2.32E-06	0.03	2.23E-06	0.04	3.27E-03	0.19	0.003	0.001	0.006	*
cg17822007	--	3	--	155463780	2.37E-06	0.03	1.36E-04	0.15	2.11E-05	0.13	0.007	0.003	0.011	-
cg14030997	--	9	--	108420639	2.49E-06	0.03	2.42E-02	0.50	4.04E-05	0.13	-0.004	-0.007	-0.002	-
cg14679558	--	13	--	21652153	2.70E-06	0.03	1.33E-03	0.27	8.21E-04	0.16	-0.002	-0.004	-0.001	-
cg12637205	<i>CYLD</i>	16	5'UTR	50776628	2.71E-06	0.03	7.45E-04	0.24	4.64E-04	0.16	0.004	0.001	0.007	-
cg09090582	<i>CNPY1</i>	7	5'UTR	155324691	2.77E-06	0.03	2.74E-04	0.18	2.57E-05	0.13	0.009	0.004	0.013	-
cg03500617	--	16	--	74812570	2.86E-06	0.03	7.52E-04	0.24	1.85E-04	0.15	-0.005	-0.008	-0.002	-
cg10493855	<i>TTC7B</i>	14	Body	91087586	2.89E-06	0.03	1.71E-04	0.16	1.64E-04	0.15	-0.008	-0.015	-0.002	-
cg14945917	--	4	--	38145641	2.95E-06	0.03	1.72E-04	0.16	6.98E-05	0.13	-0.005	-0.008	-0.002	-
cg16539640	<i>CYFIPI</i>	15	Body	22945028	2.98E-06	0.03	2.54E-03	0.31	5.58E-04	0.16	-0.002	-0.003	-0.001	-
cg02564272	<i>MAN1A1</i>	6	Body	119507963	3.04E-06	0.03	1.66E-02	0.46	4.17E-03	0.19	-0.009	-0.018	-0.001	-
cg18073471	<i>PRDM8</i>	4	5'UTR	81119198	3.24E-06	0.03	5.62E-04	0.22	3.23E-03	0.19	0.006	0.002	0.011	-

cg27568885	<i>GCNT3</i>	15	Body	59911449	3.45E-06	0.03	3.08E-08	0.01	3.13E-07	0.10	-0.003	-0.005	-0.002	*
cg13468418	--	4	--	186048907	3.54E-06	0.03	1.04E-05	0.07	1.17E-04	0.14	0.003	0.002	0.004	-
cg16560389	--	10	--	133318201	3.60E-06	0.03	4.31E-04	0.20	3.16E-05	0.13	-0.003	-0.006	-0.001	-
cg16210526	--	10	--	134663864	3.71E-06	0.03	4.93E-05	0.11	3.62E-04	0.16	-0.004	-0.006	-0.001	-
cg13521097	<i>FERMT2</i>	14	5'UTR	53417433	3.85E-06	0.03	8.06E-04	0.24	7.60E-04	0.16	0.002	0.001	0.003	-
cg15799267	<i>ALOX15B</i>	17	5'UTR	7942406	4.08E-06	0.03	2.62E-03	0.32	5.26E-06	0.12	0.007	0.005	0.01	-
cg19270277	<i>CROCC</i>	1	Body	17296995	4.10E-06	0.03	1.64E-04	0.15	2.29E-05	0.13	-0.006	-0.009	-0.003	-
cg04375213	<i>DCPIB</i>	12	Body	2113435	4.12E-06	0.03	4.06E-06	0.05	7.33E-06	0.12	0.001	0.001	0.002	*
cg13109184	<i>LYST</i>	1	--	236029439	4.40E-06	0.03	4.95E-04	0.21	7.00E-03	0.20	0.005	0.001	0.01	-
cg22902505	<i>PRDM8</i>	4	5'UTR	81119473	4.79E-06	0.04	4.50E-04	0.20	5.07E-05	0.13	0.009	0.005	0.015	-
cg08614562	<i>KIF1A</i>	2	Body	241665572	5.13E-06	0.04	2.42E-03	0.31	9.33E-04	0.16	-0.004	-0.007	-0.001	-
cg19864758	<i>PCSK2</i>	20	TSS1500	17206720	5.19E-06	0.04	2.90E-03	0.32	9.14E-05	0.13	0.003	0.001	0.005	-
cg27063720	<i>EP400NL</i>	12	Body	132568987	5.23E-06	0.04	1.88E-05	0.08	8.97E-05	0.13	0.004	0.002	0.007	-
cg24604043	<i>SLC39A3</i>	19	TSS1500	2740392	5.34E-06	0.04	4.17E-03	0.35	8.92E-03	0.21	0.004	0.001	0.008	-
cg15136913	--	10	--	134893540	5.38E-06	0.04	9.07E-05	0.13	8.04E-05	0.13	-0.005	-0.009	-0.002	-
cg19091677	<i>HMGB2</i>	4	TSS1500	174255518	5.44E-06	0.04	2.13E-04	0.17	7.46E-04	0.16	0.004	0.001	0.007	-
cg10625723	--	4	--	6235503	5.50E-06	0.04	1.73E-02	0.47	2.08E-03	0.18	-0.002	-0.004	-0.001	-
cg07821496	<i>TDRKH</i>	1	5'UTR	151762942	5.51E-06	0.04	5.99E-04	0.22	3.25E-05	0.13	0.005	0.002	0.007	-
cg08294772	--	8	--	138135392	5.52E-06	0.04	9.92E-03	0.42	2.38E-05	0.13	0.007	0.004	0.01	-
cg26309691	<i>SCCPDH</i>	1	Body	246887944	6.14E-06	0.04	5.21E-03	0.36	5.23E-04	0.16	0.003	0.001	0.005	-
cg21074877	--	14	--	23481968	6.54E-06	0.04	1.16E-02	0.43	5.31E-04	0.16	-0.002	-0.003	-0.001	-
cg19827167	<i>MIR760</i>	1	TSS200	94312206	6.56E-06	0.04	4.61E-03	0.35	5.63E-03	0.20	0.001	0	0.003	-
cg27330720	<i>FBXL20</i>	17	TSS1500	37558981	6.67E-06	0.04	3.79E-05	0.10	6.64E-03	0.20	0.004	0.001	0.006	-
cg05130304	<i>C3orf23</i>	3	TSS1500	44379503	6.72E-06	0.04	3.64E-04	0.20	9.69E-03	0.21	0.004	0	0.007	-
cg26509269	--	17	--	34970306	6.89E-06	0.04	4.28E-04	0.20	1.41E-04	0.14	-0.004	-0.007	-0.002	-
cg27496299	<i>DNAJB6</i>	7	Body	157171202	6.90E-06	0.04	2.07E-03	0.30	1.05E-04	0.13	-0.004	-0.007	-0.002	-
cg02458885	<i>PRDM8</i>	4	5'UTR	81119249	6.93E-06	0.04	2.06E-04	0.17	2.33E-04	0.15	0.009	0.004	0.015	-
cg21385432	<i>EP400</i>	12	Body	132512858	7.04E-06	0.04	4.71E-03	0.36	4.05E-04	0.16	-0.003	-0.006	-0.001	-
cg06874656	<i>NTM</i>	11	TSS1500	131780353	7.10E-06	0.04	1.81E-03	0.29	5.98E-03	0.20	0.004	0.001	0.008	-
cg21239691	<i>GEMIN8</i>	X	TSS200	14048191	7.20E-06	0.04	7.54E-03	0.39	1.51E-05	0.13	0.006	0.003	0.01	-
cg00895834	<i>PRDM16</i>	1	Body	3147966	7.20E-06	0.04	1.73E-04	0.16	3.73E-05	0.13	-0.005	-0.008	-0.003	-
cg21473728	<i>MYOM2</i>	8	Body	2031651	7.42E-06	0.04	1.73E-03	0.29	1.27E-03	0.17	-0.006	-0.009	-0.001	-

cg10390589	<i>SAE1</i>	19	TSS200	47634047	7.64E-06	0.04	4.33E-03	0.35	0.01	0.23	0.002	0	0.004	-
cg10246772	<i>IGF1R</i>	15	Body	99250916	7.90E-06	0.04	3.75E-02	0.54	4.68E-03	0.19	-0.004	-0.008	-0.001	-
cg02514021	<i>FLJ43663</i>	7	Body	130791171	8.24E-06	0.04	6.20E-04	0.22	3.49E-03	0.19	0.006	0.001	0.012	-
cg10609984	<i>ZNF25</i>	10	TSS200	38265593	8.43E-06	0.04	3.31E-05	0.10	1.49E-03	0.17	0.003	0.001	0.006	-
cg25087154	<i>IL1RAP</i>	3	TSS1500	190231338	8.47E-06	0.04	9.19E-04	0.25	2.63E-03	0.18	0.005	0.001	0.008	-
ch.11.150171F	<i>NUP98</i>	11	Body	3739920	9.00E-06	0.04	4.58E-04	0.20	8.88E-04	0.16	0.005	0.002	0.008	-
cg23284284	<i>GIGYF2</i>	2	TSS200	233561917	9.02E-06	0.04	6.68E-03	0.38	0.01	0.23	0.006	0.001	0.01	-
cg01093285	<i>PTPRN2</i>	7	Body	157436506	9.38E-06	0.04	1.68E-03	0.29	4.52E-04	0.16	-0.006	-0.009	-0.002	-
cg27632471	<i>C20orf96</i>	20	Body	259123	9.42E-06	0.04	1.43E-03	0.28	1.67E-03	0.17	-0.004	-0.007	-0.001	-
cg12411309	<i>SMUG1</i>	12	5'UTR	54582659	9.51E-06	0.04	2.22E-03	0.30	3.65E-04	0.16	0.004	0.002	0.006	-
cg17341361	<i>TNRC18</i>	7	Body	5414170	9.51E-06	0.04	1.58E-02	0.46	8.24E-04	0.16	-0.003	-0.004	-0.001	-
cg07124687	--	6	--	28956332	9.71E-06	0.04	5.01E-05	0.11	1.57E-04	0.14	0.005	0.002	0.008	-
cg12154976	<i>RASGEF1C</i>	5	5'UTR	179585198	9.84E-06	0.04	9.99E-05	0.13	1.30E-03	0.17	-0.006	-0.01	-0.002	-
cg12398448	<i>IGF1R</i>	15	Body	99251461	9.87E-06	0.04	2.51E-03	0.31	3.70E-05	0.13	-0.007	-0.013	-0.003	-
cg10462751	<i>RIC8B</i>	12	TSS200	107168330	1.03E-05	0.05	6.89E-04	0.23	9.50E-03	0.21	0.005	0.001	0.01	-
cg04204072	<i>THUMPD1</i>	16	1stExon	20752857	1.04E-05	0.05	1.28E-02	0.44	1.61E-04	0.14	0.003	0.001	0.006	-
cg10962490	<i>GLIS1</i>	1	5'UTR	54072456	1.05E-05	0.05	4.55E-04	0.20	1.31E-04	0.14	-0.004	-0.006	-0.001	-
cg13653274	--	10	--	132632928	1.07E-05	0.05	1.18E-03	0.26	0.04	0.28	-0.006	-0.012	-0.001	-
cg15472403	<i>OSCAR</i>	19	Body	54599455	1.09E-05	0.05	1.22E-03	0.27	8.18E-04	0.16	0.003	0.001	0.005	-
cg00014152	<i>WDR13</i>	X	Body	48457128	1.10E-05	0.05	2.40E-04	0.18	3.64E-04	0.16	-0.004	-0.007	-0.001	-
cg25247351	<i>HLA-DMB</i>	6	1stExon	32908794	1.11E-05	0.05	1.46E-04	0.15	1.77E-03	0.17	0.003	0.001	0.005	-
cg03156396	<i>MSLN</i>	16	Body	816177	1.13E-05	0.05	1.30E-05	0.07	4.79E-05	0.13	-0.006	-0.01	-0.002	-
cg10650870	<i>TNPO1</i>	5	Body	72144764	1.15E-05	0.05	1.31E-03	0.27	1.76E-04	0.15	0.002	0.001	0.003	-
cg01487433	<i>CILP2</i>	19	TSS200	19648987	1.15E-05	0.05	2.60E-04	0.18	1.78E-05	0.13	-0.002	-0.003	-0.001	-
cg22533689	<i>EPHA2</i>	1	Body	16464479	1.16E-05	0.05	6.08E-03	0.37	0.01	0.22	-0.005	-0.009	-0.001	-
cg13735965	<i>ZNF616</i>	19	TSS1500	52643487	1.18E-05	0.05	5.75E-03	0.37	5.42E-04	0.16	0.005	0.002	0.008	-
cg07307426	<i>DET1</i>	15	5'UTR	89089587	1.18E-05	0.05	2.40E-04	0.18	0.01	0.23	0.004	0	0.008	-
cg25002318	<i>TRPV1</i>	17	Body	3471868	1.20E-05	0.05	1.13E-03	0.26	5.74E-03	0.20	-0.005	-0.009	-0.001	-
cg19554389	<i>WNT5A</i>	3	1stExon	55521134	1.20E-05	0.05	1.92E-03	0.30	0.01	0.23	0.003	0.001	0.005	-
cg16953816	<i>VPS37B</i>	12	3'UTR	123349952	1.22E-05	0.05	7.14E-03	0.39	5.59E-04	0.16	-0.007	-0.01	-0.002	-
cg14604000	<i>C5orf13; NREP</i>	5	TSS1500	111093875	1.24E-05	0.05	7.20E-06	0.06	2.23E-05	0.13	0.003	0.001	0.006	-
cg11969467	<i>MRPS14</i>	1	TSS200	174992598	1.24E-05	0.05	3.45E-04	0.19	0.05	0.31	0.002	0	0.003	-

cg03998119	<i>PTPN21</i>	14	Body	88945315	1.25E-05	0.05	0.06	0.59	0.05	0.31	-0.005	-0.012	0	-
cg03041046	<i>SPRYD3</i>	12	5'UTR	53473136	1.27E-05	0.05	1.10E-05	0.07	9.38E-04	0.16	0.005	0.001	0.009	-
cg25051341	<i>PRDM13</i>	6	Body	100061307	1.30E-05	0.05	0.67	0.86	3.45E-03	0.19	0.002	0	0.005	-
cg01407073	<i>NAPILI</i>	12	TSS200	76478898	1.30E-05	0.05	9.16E-03	0.41	6.63E-04	0.16	0.004	0.001	0.007	-
cg15874300	<i>CRBN</i>	3	Body	3221199	1.31E-05	0.05	1.30E-03	0.27	4.33E-04	0.16	0.003	0.001	0.004	-
cg13144843	--	3	--	174158740	1.33E-05	0.05	9.94E-03	0.42	7.50E-04	0.16	0.003	0.001	0.004	-
cg26163537	<i>GRB10</i>	7	TSS1500	50861592	1.37E-05	0.05	5.83E-05	0.11	4.75E-04	0.16	0.004	0.002	0.007	-
cg20657691	<i>RBM3</i>	X	TSS1500	48432562	1.38E-05	0.05	2.78E-04	0.18	0.01	0.22	0.006	0	0.012	-
cg06616055	<i>MUPCDH</i>	11	Body	623756	1.42E-05	0.05	1.65E-04	0.16	3.76E-05	0.13	-0.007	-0.011	-0.003	-

N.B. Genes with multiple significant probes are highlighted in blue. Standardized Beta estimates are used as a measure of effect size, where an effect of 0.10 is small effect, an effect of 0.24 is a medium effect, and an effect of 0.37 is a large effect. Values in grey represent non-significant estimates.

^a**Original analysis:** P-values and genome-wide corrected Q-values from the original epigenome-wide association analyses (i.e. correcting for age, sex and ethnicity)

^b**SVA:** P-values and genome-wide corrected Q-values after adjusting for the 11 surrogate variables identified via surrogate variable analysis.

^c**Winsorizing:** P-values and genome-wide corrected Q-values after winsorizing <5% and >95% values of score distribution in order to minimize the impact of outliers.

^d**Bootstrapping:** Unstandardized betas and 95% Confidence Intervals (CIs) after bootstrapping estimates 10,000 times.

^e**High confidence associations** (marked with *) are defined as having (i) a significant SVA q-value; (ii) a significant winsorized p-value; and (iii) bootstrapped CIs that do not cross zero.

OS6: Enriched biological processes for genes associated with epigenetic variation that is unique to each maltreatment type

GO Pathway		<i>N</i> genes in input list	Total <i>N</i> in pathway	%	<i>p</i> -value	<i>Genes</i>
Physical abuse						
1	regulation of cardiac muscle hypertrophy	3	24	13%	1.04E-12	<i>RGS2;EDN1;ADRB1</i>
2	negative regulation of smooth muscle contraction	2	12	17%	9.01E-12	<i>RGS2;ADRB1</i>
3	superoxide metabolic process	3	31	10%	6.38E-10	<i>EDN1;MT3;PREX1</i>
4	metanephric nephron tubule development	2	15	13%	1.36E-09	<i>CALB1;ACAT1</i>
5	oocyte maturation	2	16	13%	4.15E-09	<i>BRCA2;REC8</i>
6	positive regulation of protein dephosphorylation	2	16	13%	4.90E-09	<i>NELF;CALM1</i>
7	fucose metabolic process	2	16	13%	5.22E-09	<i>B3GALTL;FUT5</i>
8	regulation of keratinocyte proliferation	2	17	12%	1.51E-08	<i>CASK;PRKD1</i>
9	positive regulation of heart rate	2	18	11%	4.04E-08	<i>EDN1;ADRB1</i>
10	male meiosis I	2	19	11%	1.03E-07	<i>BRCA2;REC8</i>
11	regulation of urine volume	2	20	10%	2.19E-07	<i>EDN1;ADRB1</i>
12	glycogen catabolic process	2	20	10%	2.32E-07	<i>ADRB1;CALM1</i>
13	regulation of oxidoreductase activity	4	73	5%	3.26E-07	<i>GLA;EDN1;CALM1;MT3</i>
14	negative regulation of oxidoreductase activity	2	21	10%	4.64E-07	<i>GLA;MT3</i>
15	pyrimidine nucleoside triphosphate biosynthetic process	2	21	10%	4.67E-07	<i>RP2;TBPL1</i>
16	positive regulation of cation channel activity	2	23	9%	1.55E-06	<i>ADRB1;CALM1</i>

17	response to X-ray	2	24	8%	2.49E-06	<i>ERCC8;BRCA2</i>
18	positive regulation of blood vessel endothelial cell migration	2	25	8%	4.29E-06	<i>FGF2;PRKD1</i>
19	fear response	2	27	7%	9.95E-06	<i>ADRB1;GABRA5</i>
20	regulation of wound healing	4	94	4%	1.30E-05	<i>CASK;GP5;FGF2;EDN1</i>
21	negative regulation of stress-activated protein kinase signaling cascade	2	29	7%	2.48E-05	<i>HDAC3;MPP2</i>
22	regulation of glycoprotein biosynthetic process	2	29	7%	2.54E-05	<i>ACAT1;MT3</i>
23	brown fat cell differentiation	2	30	7%	2.83E-05	<i>RGS2;ADRB1</i>
24	positive regulation of osteoblast differentiation	3	62	5%	3.17E-05	<i>BMPR1B;FGF2;PRKD1</i>
25	positive regulation of DNA repair	2	30	7%	3.31E-05	<i>ERCC8;MPP2</i>
26	protein kinase B signaling	2	30	7%	3.43E-05	<i>RPS6KB2;MT3</i>
27	negative regulation of endocytosis	2	30	7%	3.43E-05	<i>PRKD1;PRTN3</i>
28	eye photoreceptor cell development	2	31	6%	4.95E-05	<i>CRB1;BHLHE23</i>
29	activation of adenylate cyclase activity	2	33	6%	7.98E-05	<i>ADRB1;CALM1</i>
30	positive regulation of muscle contraction	2	33	6%	9.09E-05	<i>RGS2;EDN1</i>
31	regulation of cardiac muscle contraction	3	70	4%	9.79E-05	<i>RGS2;ADRB1;CALM1</i>
32	regulation of cytokinesis	2	35	6%	1.49E-04	<i>BRCA2;CALM1</i>
33	regulation of multicellular organism growth	3	81	4%	4.75E-04	<i>HDAC3;ADRB1;GDF5</i>
34	negative regulation of purine nucleotide metabolic process	2	42	5%	6.16E-04	<i>CPEB2;EDN1</i>
35	connective tissue development	5	198	3%	6.26E-04	<i>BMPR1B;FGF2;EDN1;ACAT1;GDF5</i>

36	regulation of phospholipase activity	3	87	3%	7.38E-04	<i>RGS2;FGF2;CALM1</i>
37	regulation of cell development	10	590	2%	8.27E-04	<i>FGF2;EDN1;NELF;ADRB1;LRRC4C;PRKD1;MT3;PREX1;BHLHE23;GDF5</i>
38	regulation of G-protein coupled receptor protein signaling pathway	4	140	3%	8.33E-04	<i>RGS2;EDN1;CALM1;KLK5</i>
39	dorsal/ventral pattern formation	3	94	3%	1.37E-03	<i>DISP1;BMPR1B;EDN1</i>
40	negative regulation of epithelial cell proliferation	3	96	3%	1.62E-03	<i>CASK;BRCA2;GDF5</i>
41	cellular response to abiotic stimulus	5	223	2%	2.26E-03	<i>TNFRSF8;TNFRSF10A;NELF;SNCG;CALM1</i>
42	double-strand break repair via homologous recombination	2	52	4%	2.82E-03	<i>BRCA2;REC8</i>
43	regulation of pH	2	52	4%	2.89E-03	<i>EDN1;ATP5B</i>
44	inositol phosphate metabolic process	2	56	4%	4.02E-03	<i>FGF2;CALM1</i>
45	regulation of cell death	16	1284	1%	4.75E-03	<i>MST4;TNFRSF8;NLRP3;BMPR1B;FGF2;HDAC3;IL20RA;EDN1;NEL;ADRB1;PRKD1;GABRA5;RNPS1;MT3;BHLHE23;GDF5</i>
46	negative regulation of NF-kappaB transcription factor activity	2	62	3%	7.65E-03	<i>ZCCHC11;NLRP3</i>

Physical neglect

1	regulation of cholesterol efflux	4	17	24%	2.91E-11	<i>ABCA1;LRP1;CEP;APOE</i>
2	negative regulation of multicellular organism growth	3	12	25%	2.12E-09	<i>ANKRD26;ATXN2;BBS2</i>
3	negative regulation of endothelial cell migration	5	31	16%	2.94E-09	<i>CXCL13;ACVRL1;APOH;PTPRM;APOE</i>
4	mitotic G2 DNA damage checkpoint	3	14	21%	4.08E-08	<i>CDC2;CDK1;C10orf90</i>
5	spermatid nucleus differentiation	3	15	20%	1.37E-07	<i>KDM3A;HIST1H2BA;DMRTC2</i>

6	negative regulation of endothelial cell proliferation	4	26	15%	2.25E-07	<i>ACVRL1;APOH;PTPRM;APOE</i>
7	receptor-mediated endocytosis	9	113	8%	1.03E-06	<i>FCHO2;LRP12;LRP1;NEDD4;CETP;COLEC12;DNM2;LDLR;APOE</i>
8	endocytosis	19	372	5%	2.09E-06	<i>CDC42SE1;DNM3;STON1-GTF2A1L;ELMOD2;FCHO2;LRP12;DENND1A;ABCA1;GAPVD1;EEA1;LRP1;NEDD4;CETP;DLG4;MRC2;COLEC12;DNM2;LDLR;APOE</i>
9	phospholipid transport	5	45	11%	2.72E-06	<i>ATP11B;ABCA1;CETP;LDLR;APOE</i>
10	cerebellar cortex development	5	47	11%	4.86E-06	<i>HSPA5;MDK;ATXN2;GLI1;NEUROD2</i>
11	microtubule bundle formation	4	32	13%	5.31E-06	<i>KIF20A;MAP1B;BBS2;MARK4</i>
12	rRNA transcription	3	20	15%	8.54E-06	<i>GTF3C3;GTF3A;CD3EAP</i>
13	intracellular pH reduction	3	20	15%	8.70E-06	<i>CLIC4;CLCN3;AQP11</i>
14	G-protein coupled glutamate receptor signaling pathway	2	10	20%	1.30E-05	<i>GRM8;GRM5</i>
15	negative regulation of receptor-mediated endocytosis	2	10	20%	1.34E-05	<i>ATXN2;DLG4</i>
16	synaptic vesicle endocytosis	3	21	14%	1.51E-05	<i>DENND1A;EEA1;DLG4</i>
17	polyamine metabolic process	3	21	14%	1.57E-05	<i>ADH1;AZIN1;MTAP</i>
18	response to copper ion	3	22	14%	2.71E-05	<i>ABP1;CDC2;CDK1</i>
19	regulation of endothelial cell chemotaxis	2	11	18%	3.66E-05	<i>CXCL13;HSPB1</i>
20	receptor catabolic process	2	11	18%	3.69E-05	<i>GPRASP1;NEDD4</i>
21	regulation of platelet-derived growth factor receptor signaling pathway	2	11	18%	3.70E-05	<i>LRP1;F7</i>

22	peptidyl-glutamic acid carboxylation	2	11	18%	3.76E-05	<i>F7;F10</i>
23	protein localization to kinetochore	2	11	18%	3.77E-05	<i>CDC2;CDK1</i>
24	negative regulation of muscle cell apoptotic process	3	23	13%	4.24E-05	<i>BAG3;NACA;APOH</i>
25	negative regulation of signal transduction	30	814	4%	5.40E-05	<i>GPRASP1;GPR161;ERRF11;CHRD;CX3CR1;DLK2;DACT2;LATS1;HSPB1;CRHR2;FZD1;FOXH1;HSPA5;MLLT3;DBC1;ANKRD26;GRM5;LGR4;FAM89B;MAPKAPK5;LRP1;GLI1;FOXO1;DLK1;DACT1;NEDD4;NLRC3;GLIS2;NANOS3;APOE</i>
26	regulation of Cdc42 protein signal transduction	3	24	13%	6.99E-05	<i>FGD1;ABCA1;APOE</i>
27	cellular response to inorganic substance	7	99	7%	7.71E-05	<i>CLIC4;ABP1;ASPH;FOXO1;MT1L;CES1;NEUROD2</i>
28	positive regulation of skeletal muscle tissue development	2	12	17%	8.57E-05	<i>CDON;NACA</i>
29	mitochondrial calcium ion homeostasis	2	12	17%	8.79E-05	<i>CCDC90A;ATP2A1</i>
30	histone H3-K4 trimethylation	2	12	17%	8.80E-05	<i>MLL2;ARID4A</i>
31	methionine biosynthetic process	2	12	17%	8.81E-05	<i>ADII;MTAP</i>
32	cell migration involved in gastrulation	2	12	17%	8.85E-05	<i>FOXH1;MESP2</i>
33	lipoprotein metabolic process	7	100	7%	8.85E-05	<i>HHAT;ABCA1;LRP1;CETP;MPPE1;LDLR;APOE</i>
34	negative regulation of smoothened signaling pathway	3	25	12%	1.02E-04	<i>GPR161;CHRD;GLIS2</i>
35	transcription from RNA polymerase III promoter	4	42	10%	1.44E-04	<i>GTF3C3;POLR3G;CRCP;GTF3A</i>
36	histone H2A acetylation	2	13	15%	1.77E-04	<i>DMAPI;BRD8</i>

OS7: Enriched biological processes for genes associated with epigenetic variation that is shared across maltreatment types (physical abuse, sexual abuse and neglect)

GO Pathway	<i>N</i> genes in input list	Total <i>N</i> in pathway	%	<i>p</i> -value	<i>Genes</i>
1 regulation of nervous system development	133	530	25.09	4.20E-10	<i>DMD;MECP2;NLGN3;SOX3;DAB1;NTRK1;VANGL2;WNT3A;ARHGEF2;LMX1A;LRP8;AGRN;DISC1;SKI;TNR;NGF;ABL2;CNTN2;REN;HOXD3;OBSL1;GLI2;SOX11;RTN4;NRXN1;SERPINE2;BCL11A;STK25;ITM2C;SHOX2;PTPRG;EPHB3;ROBO1;ETV5;WNT5A;GHSR;SKIL;ODZ3;SFRP2;NKX6;FGFR3;HTT;SEMA6A;ACSL6;NEUROG1;C5orf13;ZSWIM6;OTP;IL6ST;THBS2;SYNGAP1;TFAP2A;PACSIN1;FYN;KIAA0319;GLI3;LIMK1;YWHAG;COBL;PTK2B;STK3;PTK2;STMN2;ZHX2;GDF6;TG;LZTS1;NOTCH1;DAB2IP;NKX62;KNDC1;CAMK1D;TCF7L2;ITGB1;VAX1;CPEB3;ZNF488;SLIT1;PTEN;PAX2;PAX6;BDNF;ODZ4;HCCA2;ASCL2;PVRL1;RELA;CEND1;LHX5;LRP6;FBXW8;FKBP4;SSH1;ULK1;RNF10;STK24;EDNRB;PRKCH;FOXA1;BCL11B;AKT1;SIX4;SNW1;SEMA7A;NPTN;LINGO1;ZFHX3;MAPK8IP3;AATK;HOXB3;ACCN1;SEZ6;NTN1;STAT3;MED1;TGIF1;ADCYAP1;MBP;BCL2;CACNA1A;PALM;APC2;PLK5P;TCF3;NOTCH3;BMP7;FOXA2;CDK5RAP1;PLXNB2;EP300;CELSR1;TSPO;YPEL1</i>

2	regulation of growth	287	1468	19.55	9.48E-10	<p> <i>BCOR;FRMPD4;SHROOM2;RPS6KA3;DMD;MECP2;MID1IP1;NLGN3;SH3KBP1;GPM6B;DDX3X;FOX P3;FHL1;AMOT;TMSB15B;DAB1;NTRK1;S100A13;ARF1;GNG4;VANGL2;WNT3A;SGIP1;ARHGEF2;PR KCZ;ARHGEF16;ARHGEF10L;LMX1A;CDC42SE1;LRP8;ESPN;AGRN;CNST;DISC1;MACF1;ASAP3;SL C9A1;TNR;NGF;PEX14;ABL2;CDKN2C;CNTN2;TPR;IGFBP5;LRPPRC;OBSL1;CTNNA2;BIN1;SH3YL1; EML4;RTN4;ALMS1;NRXN1;SH3BP4;SERPINE2;BCL11A;SPTBN1;NCK2;STK25;AAK1;MERTK;ITM2C; SPAST;CGREF1;RALB;SHOX2;PTPRG;TNK2;EPHB3;WWTR1;HYAL2;BCL6;PFN2;ROBO1;ETV5;WNT5 A;GHSR;DPPA2;SKIL;AHSG;ZNF639;GPX1;CTBP1;CAMK2D;MSX1;ODZ3;SHROOM3;SFRP2;FGFR3; APBB2;ODZ2;RUFY1;SLIT3;ACSL6;SCGB3A1;NEUROG1;FGFR4;PLK2;CSF1R;MYO10;TPPP;THBS2;S YNGAP1;TRIM40;DST;FBXO5;JARID2;PARK2;SRF;PACSIN1;DDR1;PHF1;PKHD1;FYN;CDKN1A;KIA A0319;FOXK1;MAD1L1;PDGFA;PODXL;CAPZA2;LIMK1;YWHAG;IGFBP3;HOXA13;ARPC1A;GNA12; ELN;TAC1;COBL;PTK2B;ARHGEF10;STK3;MYC;ANK1;PTK2;NSMCE2;NRG1;DLC1;STMN2;CLU;ARC ;TNKS;TRPS1;LZTS1;SOX17;NOTCH1;DAB2IP;GSN;COL5A1;KNDC1;MTG1;ATAD1;CAMK1D;TCF7L2 ;ITGB1;GDF2;CPEB3;SORBS1;PRKCQ;HTRA1;SLIT1;NET1;NRG3;DKK1;PTEN;PAX2;UBE2D1;TNKS2 ;APOA1;RASGRP2;BDNF;PACSIN3;MLL;HCCA2;LRP5;PVRL1;TUB;WT1;BCL9L;CDC42EP2;NCAM1;J AM3;CDCA5;CCDC85B;EPS8;FBXW8;ESPL1;STK38L;LRP1;HRK;FKBP4;FGD6;DYNLL1;SSH1;ANAPC 5;CDKN1B;ULK1;RAPGEF3;NFE2;RB1;TBC1D4;STK24;IFT88;CDC16;PRKCH;KIF26A;FOXA1;INF2;H SP90AA1;AKT1;TRIM9;SIX4;C14orf49;SNW1;THBS1;CYFIP1;SPTBN5;ATP10A;SEMA7A;SMAD6;TPM1; EHD4;NPTN;C15orf23;MAP2K5;NUSAP1;MFGE8;GREM1;LINGO1;FAM38A;CYBA;TSC2;CDH13;FHO D1;CFDP1;SH2B1;ZNF205;ABR;GAS7;COL1A1;MYO1C;TBCD;AATK;SREBF1;MYH10;DLG4;ACCN1;S EZ6;NTN1;TEX14;TADA2A;AXIN2;TRIM37;HNF1B;CDC27;FLCN;XAF1;ADCYAP1;MBP;ACAA2;NEDD 4L;BCL2;CACNA1A;LTBP4;PALM;APC2;C3;INSR;KIAA1543;PLK5P;SMARCA4;MYO1F;BMP7;FOXA2; GTPBP5;L3MBTL;PPP1R16B;NAPB;C21orf66;BRWD1;PLXNB2;EP300;TRIOBP;CELSR1;NF2</i> </p>
---	----------------------	-----	------	-------	----------	---

3	anatomical structure morphogenesis	379	1960	19.34	4.54E-08	<p> <i>EFNB1;BCOR;SHROOM2;DLG3;RPS6KA3;DMD;HPRT1;POU3F4;COL4A5;NLGN3;FLNA;SOX3;SLITRK4;FHL1;AMOT;ARX;EDA;LICAM;DAB1;NTRK1;GNPAT;KIF26B;RYYR2;VANG2;WNT3A;SDCCAG8;GREM2;ARHGAP2;SHC1;ENAH;TBX15;LMX1A;LHX4;KCNQ4;LRP8;OBSCN;AGRN;MACF1;SKI;TNR;NGF;SOX13;ABL2;ARTN;CNTN2;NFASC;VAV3;TNN;ZNF281;FHL2;HOXD3;IGFBP5;ZEB2;HOXD8;OBSL1;CTNNA2;ATP6V1B1;GLI2;SOX11;EPAS1;WNT10A;EVX2;RTN4;ANTXR1;NRXN1;OTX1;SLC8A1;ACVR1;HOXD11;SERPINE2;TFCP2L1;EN1;SPTBN1;HOXD9;NCK2;FEZ2;CYP26B1;CREB1;MERTK;CNGA3;SPAST;SHOX2;FOXP1;TTLL3;SLITRK3;ATG7;THRB;EPHB3;MYLK;WWTR1;HYAL2;BCL6;PROK2;SIAH2;TNNC1;ROBO1;WNT5A;ATR;PAK2;SKIL;IFT122;GPX1;WHSC1;FGFR1;ABLIM2;PRDM8;IDUA;MSX1;SHROOM3;PITX2;SFRP2;NKX61;UGT8;FGFR3;NPY2R;FAT1;APBB2;FRAS1;HTT;PDGFC;CC2D2A;ODZ2;IRX4;SEMA6A;SLC12A2;SLIT3;TRIO;FGF18;NEUROG1;PPARGC1B;CSF1R;MYO10;ZSWIM6;HRH2;POU4F3;IRX2;NDST1;CSNK2B;VPS52;T;COL11A2;RPS6KA2;DST;RING1;TFAP2A;GPLD1;FOX P4;SRF;PACSIN1;DTNBP1;DDR1;PKHD1;NOTCH4;HSP90AB1;RPL10A;FYN;FLOT1;ETV7;RADIL;DN AJB6;PDGFA;PODXL;ZP3;GLI3;ZPBP;FAM20C;LIMK1;HIPK2;GBX1;HOXA13;C7orf51;ADCY1;TSPAN 12;GNA12;ELN;LFNG;WNT2;HOXA9;COBL;HOXA6;SOSTDC1;PTK2B;KIAA1688;STK3;SCRIB;EXT1;M YC;ANK1;PTK2;DUSP4;NRG1;LOXL2;DLC1;BMP1;SOX17;CHD7;RDH10;NOTCH1;VAV2;DAB2IP;PTC H1;ROR2;GSN;COL5A1;NTNG2;KNDC1;TCF7L2;ITGB1;VAX1;GDF2;FOXI2;ABLIM1;HMX3;PRKCQ;C OL13A1;GFRA1;SLIT1;NRG3;DKK1;PTEN;PAX2;ARHGAP22;UNC5B;PAX6;ALX4;LTBP3;BDNF;ODZ4; MYO7A;FLI1;BRSK2;BSX;INPPL1;LRP5;PVRL1;BARX2;HTATIP2;LRP4;WT1;AP2A2;ZBTB16;RELA;NC AM1;JAM3;CEND1;LHX5;APAF1;KDM2B;LRP6;HOXC13;NCOR2;LRP1;PRICKLE1;MYF6;CACNA1C; HOXC11;FRS2;PXN;DYNLL1;SSH1;HOXC9;NAB2;ULK1;UNC119B;IFT81;RAPGEF3;ATP8A2;FARP1;R B1;CDX2;COL4A2;PCDH8;SMAD9;ZIC5;IFT88;MEG3;FOXA1;BCL11B;SLC24A4;JAG2;HSP90AA1;BR F1;RPGRIP1;VSX2;ESRRB;SIX4;LRP10;NR2F2;THBS1;CYFIP1;IGF1R;SPTBN5;RORA;SEMA7A;RGMA; MEGF11;TPM1;ACAN;MFGE8;GREM1;ANKRD11;CACNA1H;CREBBP;IFT140;TSC2;MYH11;ZFPM1; MAPK8IP3;E2F4;CDH13;FOXF1;TUBB3;PSMB10;ABR;TNFSF12;PLCD3;GAS7;COL1A1;MYO1C;TBX4 ;MYO15A;MYH10;HOXB3;DLG4;NTN1;FOXJ1;STAT3;AXIN2;CCDC40;NPTX1;HNF1B;WNK4;MED1;Z PBP2;TGIF1;NFATC1;ONECUT2;RAX;SALL3;BCL2;LAMA1;CACNA1A;MYO9B;RYYR1;INSR;NFIC;B9D2 ;PIP5K1C;TCF3;C19orf20;TRIM28;C19orf51;TNNI3;VASP;NOTCH3;ERCC2;SMARCA4;NRTN;TGM3;G NAS;COL9A3;BMP7;FOXA2;BTBD3;MYLK2;LAMA5;PARD6B;TFAP2C;OTOR;RIPK4;PCNT;COL18A1; PLXNB2;CACNA1I;EP300;TBX1;CELSR1;NF2;MAP3K7IP1</i> </p>
---	--	-----	------	-------	----------	---

4	neurogenesis	274	1283	21.36	5.34E-08	<p> <i>EFNB1;DLG3;RPS6KA3;DMD;MECP2;HPRT1;POU3F4;COL4A5;NLGN3;CDK16;SOX3;SLITRK4;ARX;MCF2;L1CAM;DAB1;NTRK1;PRDM16;VANGL2;WNT3A;ARHGEF2;ENAH;LMX1A;LHX4;LRP8;AGRN;NAV1;DISC1;SKI;TNR;NGF;ABL2;CDKN2C;ARTN;CNTN2;NFASC;TNN;POU3F1;REN;HOXD3;OBSL1;CTNNA2;GLI2;SOX11;WNT10A;RTN4;NRXN1;SERPINE2;BCL11A;EN1;SPTBN1;HOXD9;NCK2;FEZ2;STK25;DNER;CREB1;CNGA3;ITM2C;SPAST;SHOX2;FOXP1;SLITRK3;ATG7;PTPRG;EPHB3;DGKG;KLF15;SIAH2;ROBO1;ETV5;WNT5A;PAK2;HDAC11;SKIL;HELT;ABLIM2;PRDM8;ODZ3;PITX2;NKX6-1;UGT8;FGFR3;APBB2;HTT;ODZ2;SEMA6A;SLIT3;TRIO;ACSL6;NEUROG1;C5orf13;MYO10;ZSWIM6;POU4F3;OTP;IL6ST;CSNK2B;SYNGAP1;RPS6KA2;PRDM13;DST;TFAP2A;SRF;PACSIN1;DTNBP1;HSP90AB1;FYN;FLOT1;MDGA1;KIAA0319;DAGLB;CUX1;GLI3;LIMK1;YWHAG;HIPK2;GBX1;C7orf51;ADCY1;WNT2;OGDH;COBL;PTK2B;ARHGEF10;NRBP2;KIAA1688;STK3;SCRIB;EXT1;ANK1;PTK2;RP1L1;NRG1;STMN2;ZHX2;GDF6;LZTS1;NOTCH1;VAV2;DAB2IP;PTCH1;GSN;COL5A1;NTNG2;NKX6-2;KNDCC1;KCNMA1;CAMK1D;TCF7L2;ITGB1;PSD;TACC2;VAX1;CHAT;CPEB3;ABLIM1;PRKCQ;GFR A1;ZNF488;SLIT1;PTEN;PAX2;UNC5B;PAX6;APOA1;DBX1;OPCML;NTM;BDNF;ODZ4;MYO7A;HCCA2;BRSK2;KIRREL3;ASCL2;PVRL1;DAGLA;AP2A2;RELA;NCAM1;CEND1;LHX5;LRP6;FBXW8;PHLDA1;FKBP4;CACNA1C;FRS2;EIF2B1;SSH1;NAB2;ULK1;RAB35;RNF10;ATP8A2;FARP1;RB1;STK24;COL4A2;EDNRB;PRKCH;MEG3;FOXA1;BCL11B;JAG2;RTN1;HSP90AA1;RPGRIP1;AKT1;VSX2;SIX4;SNW1;NR2F2;CYFIP1;IGF1R;SPTBN5;RORA;SEMA7A;RGMA;NPTN;LINGO1;CACNA1H;GRIN2A;ZFHX3;MYH11;MAPK8IP3;NDE1;TUBB3;GAS7;AATK;MYH10;HOXB3;DLG4;SEZ6;NTN1;RTN4RL1;STAT3;NPTX1;MED1;TGIF1;ADCYAP1;MBP;ONECUT2;SALL3;BCL2;LAMA1;CACNA1A;PALM;APC2;PIP5K1C;PLK5P;TCF3;VASP;NOTCH3;ERCC2;SMARCA4;NRTN;PIGT;COL9A3;BMP7;FOXA2;BTBD3;CDK5RAP1;PARDB6;TFAP2C;PCNT;NCAM2;PLXNB2;CACNA1I;EP300;CELSRI;TSPO;NF2</i> </p>
---	--------------	-----	------	-------	----------	--

5	neurological system process	230	1214	18.95	6.41E-08	<p>FRMPD4;SYN1;DLG3;RPS6KA3;SYP;DMD;MECP2;POU3F4;NLGN3;CHM;GPR143;NTRK1;GNG4;KC NAB2;PRKCZ;KCNQ4;ESPN;AGRN;CACNA1E;GPR88;DISC1;HTR6;TNR;NGF;CNTN2;NFASC;ABCA4; GRIK3;GNB1;CTNNA2;ATP6V1B1;EPAS1;NRXN1;SERPINE2;EFEMP1;TRPM8;IL1RN;CREB1;CNGA3; HRH1;ATG7;THRB;EPHB3;PROK2;TNNC1;ETV5;WNT5A;GHSR;MME;GPX1;SORCS2;CAMK2D;CPLX 1;PPP3CA;PDE6B;WDR1;NPY2R;HTT;GRM6;SLC12A2;HMGCR;PLK2;SLC6A3;HRH2;POU4F3;KCNIP 1;PDE6A;GABBR1;GRM4;THBS2;COL11A2;SYNGAP1;ITPR3;RPS6KA2;SLC29A1;TFAP2A;GABRR1;SR F;PACSIN1;DTNBP1;EYS;FYN;STX7;NQO2;GRM1;DPP6;GRM8;CHRM2;DAGLB;POU6F2;PRKAR1B;K CNH2;NPTX2;GBX1;CADPS2;ADCY1;TAS2R3;TAC1;ATP6V0A4;TSNARE1;SCRIB;DLGAP2;PTK2;RP1L 1;NRG1;ARC;CHD7;RDH10;DAB2IP;NKX6- 2;ATAD1;KCNMA1;CDH23;CHAT;CPEB3;ABLIM1;HMX3;CAMK2G;GAD2;SLIT1;NET1;PTEN;PAX2;S ORCS1;KCNQ1;SLC6A5;PAX6;ABCC8;BDNF;MYO7A;CALCA;PVRL1;DAGLA;MTNR1B;DRD4;SHANK2 ;TUB;AP2A2;CCKBR;RIC3;FOSL1;JAM3;KCNA4;OR52D1;LRP6;PRR4;AAAS;VAMP1;CACNA1C;GRIN2 B;KCNA6;CDKN1B;LIN7A;KCNH3;ALDH2;ATP8A2;FGF14;PCDH8;HTR2A;EDNRB;PRIMA1;KCNK10; SLC24A4;RPGRIPI;CPNE6;VSX2;TRIM9;SSTR1;SIX4;GPR176;APBA2;IGDCC3;RLBP1;GABRG3;CDH8 ;A2BP1;ADCY9;GRIN2A;JPH3;CDH3;NOB1;ABR;COL1A1;MYO15A;MYH10;DLG4;ACCN1;SEZ6;KCN H4;CHRN1;CAMKK1;CACNG4;NPTX1;DLGAP1;ADCYAP1;BRUNOL4;MBP;LOXHD1;RAX;KCNG2;C ACNA1A;APC2;UNC13A;GNG8;AP3D1;KCNJ14;PDE4A;PIP5K1C;GNG7;KPTN;GRIN2D;C19orf20;TNN I3;CEACAM16;GNAS;DNAJC5;MYLK2;NAPB;TMC2;OTOR;COL18A1;KCNJ6;NCAM2;CACNA1I;COMT ;TBX1;TSPO;PANX2;SYN3;RASD2</p>
---	-----------------------------	-----	------	-------	----------	--

6	organ morphogenesis	171	791	21.62	1.22E-07	<i>BCOR;SHROOM2;POU3F4;SOX3;FHL1;EDA;KIF26B;RYR2;VANGL2;WNT3A;TBX15;LHX4;KCNQ4;SKI;FHL2;HOXD3;IGFBP5;HOXD8;CTNNA2;ATP6V1B1;GLI2;SOX11;WNT10A;RTN4;OTX1;SLC8A1;ACVR1;HOXD11;HOXD9;CYP26B1;CNGA3;SHOX2;THRB;MYLK;HYAL2;TNNC1;WNT5A;IFT122;WHSC1;FGFRL1;IDUA;MSX1;PITX2;SFRP2;NKX6-1;FGFR3;NPY2R;HTT;PDGFC;IRX4;SEMA6A;SLIT3;FGF18;NEUROG1;PPARGC1B;POU4F3;IRX2;NDST1;T;COL11A2;RING1;TFAP2A;SRF;ETV7;PDGFA;GLI3;FAM20C;HIPK2;HOXA13;TSPAN12;ELN;LFNG;WNT2;HOXA6;SOSTDC1;PTK2;NRG1;DLC1;BMP1;SOX17;CHD7;RDH10;NOTCH1;PTCH1;ROR2;COL5A1;TCF7L2;ABLIM1;HMX3;COL13A1;SLIT1;PTEN;PAX2;PAX6;ALX4;LTBP3;MYO7A;FLI1;INPPL1;LRP5;PVRL1;BARX2;LRP4;WT1;RELA;KDM2B;LRP6;HOXC13;NCOR2;MYF6;HOXC11;FRS2;HOXC9;NAB2;CDX2;IFT88;FOXA1;BCL11B;SLC24A4;JAG2;RPGRIP1;VSX2;SIX4;LRP10;THBS1;IGF1R;MEGF11;TPM1;ACAN;GREM1;ANKRD11;ZFPM1;MAPK8IP3;E2F4;FOXF1;ABR;COL1A1;TBX4;MYO15A;HOXB3;NTN1;FOXJ1;STAT3;AXIN2;CCDC40;HNF1B;WNK4;MED1;ONECUT2;RAX;BCL2;LAMA1;RYR1;INSR;NFIC;TNNI3;SMARCA4;TGM3;GNAS;BMP7;FOXA2;MYLK2;LAMA5;OTOR;PCNT;COL18A1;EP300;TBX1;CELSR1;NF2;MAP3K7IP1</i>
7	regulation of mesenchymal cell apoptotic process	8	13	61.54	2.85E-07	<i>POU3F4;MSX1;HOXA13;PAX2;WT1;HNF1B;BMP7;TBX1</i>
8	regulation of glial cell proliferation	9	15	60.00	4.00E-07	<i>SKI;SOX11;ETV5;NOTCH1;ASCL2;RNF10;PRKCH;ADCYAP1;TSPO</i>

9	tube development	108	465	23.23	2.32E-06	<i>FOXP3;EDA;KIF26B;RYYR2;VANGL2;WNT3A;SDCCAG8;ENAH;SKI;ZEB2;GLI2;SOX11;EPAS1;SLC8A1;ACVR1;HOXD11;CREB1;FOXP1;THRB;ROBO1;WNT5A;DPPA2;IFT122;SHROOM3;PITX2;SFRP2;FGFR3;ADAMTS2;SLC12A2;FGF18;FGFR4;CSF1R;LOX;IRX2;CSNK2B;T;TFAP2A;FOXP4;SRF;DDR1;NOTCH4;BAT3;PDGFA;PODXL;CUX1;GLI3;CFTR;WNT2;COBL;SOSTDC1;STK3;SCRIB;MYC;DLC1;NKX26;SOX17;CHD7;RDH10;NOTCH1;DAB2IP;PTCH1;GDF2;PAX2;LTBP3;BDNF;LRP5;WT1;INSC;APAF1;KDM2B;LRP6;NCOR2;PRICKLE1;PXN;SMAD9;ZIC5;IFT88;FOXA1;SMAD6;RGMA;CYP1A2;GREM1;TSC2;CRISPLD2;MAPK8IP3;FOXF1;TBX4;SREBF1;NTN1;FOXJ1;CCDC40;HNF1B;WNK4;MED1;TGIF1;BCL2;LAMA1;CRLF1;VASP;BMP7;FOXA2;LAMA5;TFAP2C;PLXNB2;EP300;TBX1;CELSR1;MAP3K7IP1</i>
10	anterior/posterior pattern specification	54	200	27.00	3.60E-06	<i>VANGL2;WNT3A;SKI;HOXD3;ZEB2;HOXD8;OTX1;HOXD11;EN1;HOXD9;WNT5A;MSX1;SFRP2;HTT;T;RING1;SRF;GLI3;HIPK2;LFNG;HOXA9;COBL;HOXA6;ARC;SOX17;NOTCH1;ROR2;DKK1;PAX6;ALX4;MLL;LRP5;WT1;ZBTB16;KDM2B;LRP6;HOXC13;MYF6;HOXC11;FRS2;HOXC9;CDX2;PCDH8;IFT88;NR2F2;FOXF1;HOXB3;AXIN2;HNF1B;TCF3;FOXA2;EP300;TBX1;CELSR1</i>
11	muscle structure development	95	426	22.30	6.85E-06	<i>DMD;FOXP3;FHL1;RYYR2;WNT3A;OBSCN;SKI;SLC9A1;TAGLN2;FHL2;IGFBP5;OBSL1;CTNNA2;SOX11;BIN1;EPAS1;SLC8A1;ACVR1;SPEG;HOXD9;DNER;MAL;SHOX2;FOXP1;CACNA2D2;FLNB;ATG7;MYLK;TNNC1;WNT5A;SKIL;GPX1;FGFRL1;MSX1;PPP3CA;PITX2;HMGCR;SGCD;SYNE1;T;UTRN;SRF;COL19A1;FO XK1;SGCE;FLNC;ELN;WNT2;NRG1;NKX26;MSC;NOTCH1;TCF7L2;ITGB1;VAX1;CHAT;ALX4;BARX2;WT1;USP2;BCL9L;HINFP;MYF6;RB1;EDNRB;ASB2;AKT1;SIX4;NR2F2;TPM1;GREM1;CACNA1H;ZFHX3;MYH11;ZFPM1;CDH15;FOXF1;CDH3;MYH10;CHRNA1;MYH3;MAP2K6;MED1;RYYR1;TCF3;TNNT3;SMARCA4;MYLK2;LAMA5;SIK1;C21orf66;EP300;TBX1;SMTN;MAPK12</i>
12	neural tube closure	26	76	34.21	7.09E-06	<i>VANGL2;ENAH;SKI;ZEB2;WNT5A;IFT122;SHROOM3;SFRP2;T;TFAP2A;COBL;SCRIB;DLC1;PTCH1;PAX2;APAF1;KDM2B;LRP6;PRICKLE1;ZIC5;RGMA;TSC2;TGIF1;VASP;PLXNB2;CELSR1</i>
13	positive regulation of cell-cell adhesion mediated by integrin	6	10	60.00	8.39E-06	<i>WNT3A;WNT5A;PODXL;FOXA1;FAM38A;FOXA2</i>

14	establishment or maintenance of apical/basal cell polarity	10	22	45.45	1.01E-05	<i>DLG3;VANGL2;ERBB2IP;SCRIB;ANK1;CDX2;FOXF1;DLG4;FOXJ1;LAMA1</i>
15	establishment or maintenance of bipolar cell polarity	10	22	45.45	1.01E-05	<i>DLG3;VANGL2;ERBB2IP;SCRIB;ANK1;CDX2;FOXF1;DLG4;FOXJ1;LAMA1</i>
16	actin filament-based process	91	396	22.98	1.12E-05	<i>IQSEC2;DMD;FLNA;AMOT;TMSB15B;NPHP4;ARHGEF2;PRKCZ;SHC1;ENAH;ESPN;OBSCN;ABL2;OB SL1;ANTXR1;NCK2;FOXP1;IQSEC1;FLNB;BCL6;PFN2;TNNC1;GHSR;ATR;PAK2;SORBS2;ABLIM2;CA MK2D;SHROOM3;FAT1;ARHGAP26;PPARGC1B;LRRC16A;EPB41L2;TNXB;SRF;PACSIN1;DTNBP1;P HACTR1;NEDD9;DNAJB6;PDGFA;ELMO1;CAPZA2;LIMK1;ARPC1A;ELN;COBL;PTK2B;DLC1;GSN;IT GB1;SORBS1;MYO7A;HCCA2;BRSK2;INPPL1;CORO1B;CDC42EP2;ARHGEF17;TNNT3;TNNI2;EPS8;C ORO1C;FGD6;DYNLL1;SSH1;ACTN1;INF2;CDC42BPB;CFL2;SPTBN5;TPM1;MYH11;FHOD1;ABR;GA S7;MYO1C;MYH10;DLG4;FOXJ1;MYH3;BCL2;MYO9B;PIP5K1C;TNNT1;KPTN;TNNI3;VASP;TRIOBP; NF2</i>
17	negative regulation of ossification	12	32	37.50	2.33E-05	<i>BCOR;AHSG;SMURF1;PTK2B;NOTCH1;LTBP3;CALCA;LRP4;NFE2;LRP10;GREM1;BCL2</i>
18	limb development	45	159	28.30	2.34E-05	<i>SKI;GLI2;SOX11;EVX2;HOXD11;EN1;HOXD9;CYP26B1;SHOX2;WNT5A;IFT122;IDUA;MSX1;PITX2;SF RP2;TFAP2A;GLI3;HOXA13;GNA12;HOXA9;CHD7;RDH10;NOTCH1;PTCH1;DKK1;ALX4;LRP5;LRP4; ZBTB16;LRP6;HOXC13;HOXC11;IFT88;LRP10;NR2F2;GREM1;CREBBP;TBX4;MED1;RAX;SALL3;SMA RCA4;GNAS;BMP7;PCNT</i>
19	appendage development	45	159	28.30	2.34E-05	<i>SKI;GLI2;SOX11;EVX2;HOXD11;EN1;HOXD9;CYP26B1;SHOX2;WNT5A;IFT122;IDUA;MSX1;PITX2;SF RP2;TFAP2A;GLI3;HOXA13;GNA12;HOXA9;CHD7;RDH10;NOTCH1;PTCH1;DKK1;ALX4;LRP5;LRP4; ZBTB16;LRP6;HOXC13;HOXC11;IFT88;LRP10;NR2F2;GREM1;CREBBP;TBX4;MED1;RAX;SALL3;SMA RCA4;GNAS;BMP7;PCNT</i>

20	regulation of neurological system process	74	317	23.34	2.40E-05	<i>SYP;MECP2;NLGN3;GPM6B;NTRK1;GNPAT;ARF1;PRKCZ;LRP8;HTR6;SKI;SLC9A1;TNR;NGF;CNTN2;NFASC;GRIK3;POU3F1;NRXN1;SERPINE2;MAL;HRH1;CACNA2D2;PXXK;PFN2;PPP3CA;UGT8;FGFR3;NPY2R;HTT;PLK2;HRH2;SYNGAP1;ITPR3;SRF;DTNBP1;GRM1;YWHAG;TAC1;ARHGEF10;ARC;TG;NKX62;ATAD1;TCF7L2;CHAT;CPEB3;PTEN;BDNF;ODZ4;CALCA;DRD4;SHANK2;JAM3;GRIN2B;NAB2;RNF10;HTR2A;EDNRB;AKT1;NPTN;GRIN2A;JPH3;DLG4;ADCYAP1;MBP;CACNA1A;APC2;UNC13A;PRX;GRIN2D;ERCC2;NAPB;YPEL1</i>
21	positive regulation of muscle cell differentiation	20	61	32.79	2.61E-05	<i>WNT3A;CTNNA2;CYP26B1;SHOX2;FOXP1;IGFBP3;NRG1;MYF6;MEG3;SETD3;PIAS1;GREM1;ZFHX3;CDH15;CDH3;MAP2K6;BCL2;TCF3;TBX1;MAPK12</i>
22	endothelial cell migration	16	49	32.65	2.98E-05	<i>AMOT;PLEKHG5;ROBO1;GPX1;GPLD1;SRF;PTK2B;PTK2;LOXL2;ITGB1;PTEN;APOA1;CALCA;GREM1;CDH13;TNFSF12</i>
23	regulation of lipid kinase activity	13	35	37.14	3.22E-05	<i>VAV3;IRS1;FGFR3;PTK2B;PTK2;VAV2;DAB2IP;CCKBR;CD81;RB1;FLT3;RBL1;PIK3IP1</i>
24	regulation of gastrulation	11	27	40.74	3.82E-05	<i>WNT3A;IL1RN;SFRP2;SOX17;DKK1;APOA1;ODZ4;MAP2K5;HNF1B;TGIF1;FOXA2</i>
25	negative regulation of cellular component movement	39	160	24.38	4.42E-05	<i>PTPRU;IGFBP5;IL1RN;HYAL2;SFRP2;MCC;CSNK2B;SRF;PKHD1;IGFBP3;STK3;TRIB1;DLC1;TP53INP1;NOTCH1;DAB2IP;GDF2;PTEN;GTPBP4;MUC2;IFITM1;LRP1;CDKN1B;STK24;ACTN1;NR2F2;THBS1;TPM1;MAP2K5;GREM1;ABR;STAT3;ALOX15B;HDAC5;FLCN;BCL2;HAS1;ADARB1;NF2</i>
26	base-excision repair AP site formation	5	10	50.00	5.66E-05	<i>MID1;CCNO;SMUG1;MPG;MED1</i>
27	negative regulation of growth	48	215	22.33	6.94E-05	<i>DDX3X;FHL1;GNG4;WNT3A;TNR;CDKN2C;RTN4;ING5;SH3BP4;SERPINE2;BCL11A;CGREF1;MAL;HYAL2;BCL6;WNT5A;MSX1;SFRP2;FGFR3;APBB2;HTT;SLIT3;SCGB3A1;ADRB2;TRIM40;CDKN1A;FOXK1;STK3;PTK2;SOX17;DAB2IP;PTCH1;TCF7L2;GDF2;SLIT1;PTEN;WT1;CCDC85B;CDKN1B;ULK1;GREM1;RAI1;AATK;NTN1;ALOX15B;FLCN;BCL2;SMARCA4</i>
28	negative regulation of BMP signaling pathway	14	37	37.84	7.03E-05	<i>SKI;TRIM33;WNT5A;SFRP2;SMURF1;HIPK2;SOSTDC1;NOTCH1;TCF7L2;HTRA1;DKK1;SMAD6;FBN1;GREM1</i>
29	regulation of embryonic development	27	93	29.03	7.14E-05	<i>AMOT;NRK;VANGL2;WNT3A;IL1RN;NR2C2;WNT5A;SFRP2;LFNG;WNT2;SOX17;NOTCH1;DKK1;APOA1;ODZ4;LRP6;MEG3;SIX4;MAP2K5;HNF1B;TGIF1;LAMA1;INSR;BMP7;FOXA2;LAMA5;CELSR1</i>

30	multicellular organismal movement	10	27	37.04	7.40E-05	<i>VPS54;TNNC1;ITPR1;HIPK2;TNNT3;TNNT2;ATP8A2;HSP90AA1;CACNA1A;TNNT1</i>
31	musculoskeletal movement	10	27	37.04	7.40E-05	<i>VPS54;TNNC1;ITPR1;HIPK2;TNNT3;TNNT2;ATP8A2;HSP90AA1;CACNA1A;TNNT1</i>
32	hindbrain development	37	130	28.46	8.07E-05	<i>MECP2;DAB1;GNPAT;LMX1A;SDF4;CTNNA2;GLI2;NRXN1;OTX1;SERPINE2;EN1;NR2C2;ATG7;OGD H;DLC1;KND1;ITGB1;PAX6;CEND1;LHX5;KDM2B;LRP6;ULK1;SMAD9;SSTR1;RORA;SEZ6L2;MYH10;HOXB3;SEZ6;HNF1B;BCL2;CACNA1A;PTPRS;SMARCA4;FOXA2;PCNT</i>
33	positive regulation of skeletal muscle tissue development	6	12	50.00	9.39E-05	<i>SHOX2;HMGCR;SOX17;USP2;MEG3;BCL2</i>
34	hair cycle process	22	79	27.85	1.06E-04	<i>EDA;VANGL2;IGFBP5;WNT10A;PDGFA;SOSTDC1;NOTCH1;DKK1;ALX4;BARX2;LRP4;RELA;HOXC13;SOX21;AKT1;LRP10;BCL2;ERCC2;TGM3;LAMA5;TFAP2C;CELSR1</i>
35	hair follicle development	22	79	27.85	1.06E-04	<i>EDA;VANGL2;IGFBP5;WNT10A;PDGFA;SOSTDC1;NOTCH1;DKK1;ALX4;BARX2;LRP4;RELA;HOXC13;SOX21;AKT1;LRP10;BCL2;ERCC2;TGM3;LAMA5;TFAP2C;CELSR1</i>
36	molting cycle process	22	79	27.85	1.06E-04	<i>EDA;VANGL2;IGFBP5;WNT10A;PDGFA;SOSTDC1;NOTCH1;DKK1;ALX4;BARX2;LRP4;RELA;HOXC13;SOX21;AKT1;LRP10;BCL2;ERCC2;TGM3;LAMA5;TFAP2C;CELSR1</i>
37	establishment of nucleus localization	6	11	54.55	1.08E-04	<i>SYNE1;PTK2;SLIT1;SPTBN5;MYH10;NTN1</i>
38	viral entry into host cell	6	13	46.15	1.36E-04	<i>HYAL2;ZNF639;WWP1;PVRL1;CD81;WWP2</i>
39	gland development	67	285	23.51	1.45E-04	<i>SOX3;EDA;WNT3A;HOXD3;IGFBP5;GLI2;WNT10A;IRS1;HK2;SERPINE2;TFCP2L1;HOXD9;CREB1;ROBO1;WNT5A;MSX1;PITX2;SLC12A2;CSF1R;SLC6A3;HRH2;OTP;SLC29A1;DDR1;NOTCH4;GLI3;HOXA13;WNT2;HOXA9;SOSTDC1;SCRIB;NRG1;TG;NOTCH1;PTCH1;MGMT;TCF7L2;NRG3;PTEN;PAX6;APOA1;CCND1;BSX;LRP5;SF1;WT1;CCKBR;LRP6;NCOR2;FKBP4;FRS2;FOXA1;AKT1;IGF1R;FOXF1;HOXB3;NTN1;ALOX15B;MED1;ADCYAP1;BCL2;LAMA1;BMP7;LAMA5;TFAP2C;TBX1;TSPO</i>
40	mammary gland morphogenesis	18	52	34.62	1.49E-04	<i>IGFBP5;GLI2;ROBO1;WNT5A;SLC12A2;CSF1R;DDR1;GLI3;SOSTDC1;SCRIB;PTCH1;NRG3;BSX;LRP5;LRP6;NTN1;MED1;TFAP2C</i>

41	activation of MAPK activity	31	132	23.48	1.62E-04	<i>MAP3K7IP3;IKBK;IRAK1;SHC1;KIAA1804;ZAK;PROK2;WNT5A;MAPK10;C1QTNF2;DAXX;GRM4;MAP3K5;GRM1;GCK;NOD1;DAB2IP;DRD4;CD81;MAP4K2;FRS2;PXN;THBS1;PTPLAD1;MAP2K5;MAPK8IP3;MAP2K6;MAP4K1;INSR;LPAR2;MAP3K7IP1</i>
42	regulation of sequence-specific DNA binding transcription factor activity	68	344	19.77	1.91E-04	<i>MAP3K7IP3;RLIM;IKBK;FLNA;IRAK1;FOXP3;EDA;NTRK1;WNT3A;ARHGEF2;PRKCZ;LRP8;NGF;PEX14;TRAF5;HDAC4;PELI1;MAL;WNT5A;MAPK10;NKX6-1;NEUROG1;TRIM40;SRF;CARD11;HIPK2;WNT2;NOD1;TRIB1;CLU;DAB2IP;PTCH1;TRAF2;CAMK1D;TCF7L2;TAF3;FOXI2;PRKCQ;PTEN;RELA;FOSL1;LRP6;ERC1;RB1;COMMD6;PRKCH;FOXA1;AKT1;TP53BP1;MAP2K5;GREM1;WWP2;FOXF1;FOXJ1;TRIM37;HDAC5;PIAS4;TCF3;CRTCI;SMARCA4;BM P7;FOXA2;UBE2V1;RIPK4;SIK1;PRMT2;EP300;MAP3K7IP1</i>
43	negative regulation of cell fate commitment	6	13	46.15	2.01E-04	<i>WNT3A;SFRP2;SOSTDC1;SOX17;NKX6-2;DKK1</i>
44	multicellular organismal response to stress	20	67	29.85	2.13E-04	<i>MECP2;PPP3CA;NPY2R;TAC1;NET1;PTEN;SLC6A5;BDNF;CALCA;DRD4;GRIN2B;EDNRB;THBS1;HDAC5;ADCYAP1;BCL2;CACNA1A;GNG7;COMT;TSPO</i>
45	neurotransmitter biosynthetic process	7	16	43.75	2.16E-04	<i>SLC6A3;DAGLB;CHAT;GAD2;DAGLA;ALDH2;COMT</i>
46	proximal/distal pattern formation	12	34	35.29	2.17E-04	<i>GLI2;HOXD11;EN1;HOXD9;CYP26B1;IRX2;GLI3;HOXA9;LRP4;HOXC11;LRP10;GREM1</i>
47	regulation of skeletal muscle tissue development	20	61	32.79	2.96E-04	<i>TSC22D3;MBNL3;HDAC4;ACVR1;CYP26B1;SHOX2;NR1D2;HMGCR;IGFBP3;SOX17;NOTCH1;TCF7L2;DKK1;USP2;PRICKLE1;MEG3;ZFHX3;HDAC5;BCL2;TBX1</i>
48	primitive streak formation	5	10	50.00	3.04E-04	<i>WNT5A;T;SRF;LRP6;FOXA2</i>
49	endocytosis	72	372	19.35	3.40E-04	<i>CLCN5;SYP;NLGN3;SH3KBP1;REPS2;SGIP1;CDC42SE1;LRP8;CD247;PEAR1;CNTN2;VAV3;BIN1;LY75;SH3BP4;AAK1;DNER;MERTK;TNK2;RAB7A;ITPR1;AHSG;RUFY1;CYFIP2;MYO10;ADRB2;ITPR3;PACSIN1;HSP90AB1;FYN;ELMO1;LIMK1;ARPC1A;ST7;TFR2;SCRIB;PTK2;ARC;VAV2;FNBP1;MYO7A;CALCA;PACSIN3;INPPL1;LRP5;LRP4;TUB;AP2A2;LRP6;CORO1C;LRP1;HIP1R;ULK1;HSP90AA1;LRP10;THBS1;EHD4;MFGE8;TSC2;MYO1C;DLG4;RAB34;ASGR1;UNC13A;FCHO1;PIP5K1C;ABCA7;SH3GL1;PIK3R2;ICAM5;SNX5;RAB22A</i>

50	regulation of sister chromatid cohesion	5	11	45.45	3.68E-04	<i>NSMCE2;CDCA5;ESPL1;RB1;AXIN2</i>
51	response to drug	78	395	19.75	3.70E-04	<i>EBP;DAB1;NTRK1;GNPAT;PDE4B;LRP8;HTR6;SLC9A1;NGF;VAV3;BCAR3;REN;ABCG5;HDAC4;IL1RN;CREB1;FOSL2;ATR;PPP3CA;SFRP2;NKX61;HTT;CCNO;SLC6A3;LOX;RPP21;GPLD1;FYN;CDKN1A;MCM7;PDGFA;KCNH2;ADCY1;CFTR;GNA12;PTK2B;MYC;PTCH1;MGMT;ITGB1;GAD2;NET1;PTEN;KCNQ1;SLC6A5;APOA1;CCND1;BDNF;RELA;FOSL1;CDKN1B;PARP4;HTR2A;THBS1;GABRG3;CYP1A2;GRIN2A;ABCA3;CYBA;CDH3;SREBF1;RPH3AL;STAT3;HDAC5;MAP2K6;TGIF1;ADCYAP1;BCL2;APC2;PDE4A;TCF3;TBXA2R;GNAS;NFATC2;COL18A1;COMT;EP300;TSPO</i>
52	myoblast differentiation	12	35	34.29	3.88E-04	<i>EPAS1;HMGCR;T;SRF;NRG1;NOTCH1;TCF7L2;HINFP;RB1;ASB2;GREM1;MAPK12</i>
53	negative regulation of cell motility	36	156	23.08	4.10E-04	<i>PTPRU;IGFBP5;IL1RN;HYAL2;SFRP2;MCC;CSNK2B;SRF;IGFBP3;STK3;TRIB1;DLC1;TP53INP1;NOTCH1;DAB2IP;GDF2;PTEN;GTPBP4;MUC2;IFITM1;LRP1;STK24;NR2F2;THBS1;TPM1;MAP2K5;GREM1;ABR;STAT3;ALOX15B;HDAC5;FLCN;BCL2;HAS1;ADARB1;NF2</i>
54	activation of transmembrane receptor protein tyrosine kinase activity	5	11	45.45	4.25E-04	<i>PDGFC;ADRB2;NRG1;NRG3;GREM1</i>
55	response to growth factor	114	569	20.04	4.42E-04	<i>RPS6KA3;NGFRAP1;IRAK1;MCF2;ELK1;L1CAM;NTRK1;ARHGEF2;PRKCZ;ARHGEF16;SHC1;LRP8;PIK3CD;OBSCN;PLEKHG5;SKI;TRIM33;NGF;VAV3;CGN;FMOD;TPR;ARHGEF4;WNT10A;RTN4;IRS1;ACVR1;CREB1;RALB;KALRN;ACAP2;WWTR1;STAG1;HYAL2;WNT5A;ITPR1;SKIL;FGFRL1;FGFR3;TRIO;FGF18;NRG2;FGFR4;NDST1;ITPR3;RPS6KA2;FYN;CDKN1A;TBC1D7;SMURF1;MCM7;PDGFA;PRKAR1B;HIPK2;ADCY1;WNT2;MYC;DUSP4;NRG1;STMN2;NOTCH1;VAV2;DAB2IP;ITGB1;NET1;PTEN;PAX2;UBE2D1;LTBP3;AP2A2;RELA;ARHGEF17;NCOR2;FRS2;CDKN1B;RAB35;MCF2L;COL4A2;SMA D9;ARHGEF7;FLT3;AKT1;THBS1;SMAD6;MEIS2;EHD4;MAP2K5;LINGO1;ADCY9;TSC2;TNRC6A;PAR D6A;E2F4;ABR;SMURF2;COL1A1;MYO1C;STAT3;MED1;TGIF1;ADCYAP1;NEDD4L;LTBP4;INSR;PLK 5P;HAS1;SHC2;PIK3R2;RBL1;GATA5;TBX1;MAPK12;TNRC6B;MAP3K7IP1</i>

56	negative regulation of cell-cell adhesion	10	31	32.26	4.53E-04	<i>TNR;SERPINE2;IL1RN;PODXL;PTK2;GTPBP4;APOA1;MAP2K5;B4GALNT2;NF2</i>
57	extracellular structure organization	71	321	22.12	4.66E-04	<i>DMD;COL4A5;GPM6B;WNT3A;NID1;AGRN;LEPRE1;TNR;OLFML2B;FMOD;PXD;NRXN1;EFEMP1;ITGB5;ABI3BP;COL29A1;SFRP2;APBB2;COL23A1;SH3PXD2B;ADAMTS2;LOX;SMOC2;COL12A1;COL11A2;DST;TNXB;TFAP2A;COL19A1;DDR1;DNAJB6;PDGFA;ELN;CTSB;PTK2;LOXL2;BMP1;COL27A1;COL5A1;ITGB1;COL13A1;TLL2;LTBP3;LRP4;WT1;NCAM1;COL4A2;ACTN1;LRP10;THBS1;FBN1;ACAN;GREM1;MYH11;MMP15;CRISPLD2;FOXF1;COL1A1;MYO1C;TEX14;LAMA1;LTBP4;GLT25D1;PTPRS;HAS1;ERCC2;SMARCA4;COL9A3;BMP7;LAMA5;COL18A1</i>
58	asymmetric protein localization	7	17	41.18	5.29E-04	<i>SHROOM2;VANGL2;MAL;SHROOM3;ERBB2IP;SCRIB;CELSRI</i>
59	positive regulation of lipid biosynthetic process	14	47	29.79	5.39E-04	<i>MID1IP1;CREB1;ACSL6;GPLD1;ZP3;SORBS1;SIRT4;HTR2A;AKT1;IGF1R;SREBF1;NR1D1;APC2;ABCG1</i>
60	retina development in camera-type eye	29	113	25.66	5.54E-04	<i>NPHP4;SKI;GNB1;MERTK;CNGA3;PDE6B;LPCAT1;GRM6;PDE6A;TFAP2A;HIPK2;TSPAN12;CHD7;PAX2;LRP5;PVRL1;DRD4;TUB;RRM1;LRP6;MDM1;RPGRIP1;VSX2;MEGF11;MYH10;MED1;TGIF1;LAMA1;SMARCA4</i>
61	cell-type specific apoptotic process	22	83	26.51	5.72E-04	<i>RYR2;NGF;GNB1;HTT;POU4F3;RPS6KA2;TNFRSF21;GLI3;STK3;MYC;GDF6;DAB2IP;APAF1;RB1;JAG2;HSP90AA1;AKT1;AATK;BCL2;PLK5P;PIGT;TBX1</i>
62	positive regulation of B cell proliferation	11	38	28.95	5.88E-04	<i>IL13RA1;WNT3A;VAV3;PELI1;MAL;BCL6;CDKN1A;CARD11;BCL2;TCF3;NFATC2</i>
63	oligodendrocyte development	12	37	32.43	7.14E-04	<i>CNTN2;SOX11;HDAC11;FGFR3;GSN;NKX6-2;TCF7L2;ZNF488;PTEN;ODZ4;EIF2B1;ERCC2</i>
64	negative regulation of smoothened signaling pathway	9	25	36.00	7.43E-04	<i>REN;SERPINE2;IFT122;FGFR3;GLI3;PTCH1;RB1;KIF7;SALL3</i>

65	extracellular matrix organization	70	320	21.88	7.60E-04	<i>DMD;COL4A5;GPM6B;WNT3A;NID1;AGRN;LEPRE1;TNR;OLFML2B;FMOD;PXDND;NRXN1;EFEMP1;ITGB5;ABI3BP;COL29A1;SFRP2;APBB2;COL23A1;SH3PXD2B;ADAMTS2;LOX;SMOC2;COL12A1;COL11A2;DST;TNXB;TFAP2A;COL19A1;DDR1;DNAJB6;PDGFA;ELN;CTSB;PTK2;LOXL2;BMP1;COL27A1;COL5A1;ITGB1;COL13A1;TLL2;LTBP3;LRP4;WT1;NCAM1;COL4A2;ACTN1;LRP10;THBS1;FBN1;ACAN;GREM1;MYH11;MMP15;CRISPLD2;FOXF1;COL1A1;MYO1C;LAMA1;LTBP4;GLT25D1;PTPRS;HAS1;ERCC2;SMARCA4;COL9A3;BMP7;LAMA5;COL18A1</i>
66	ventral spinal cord interneuron specification	6	11	54.55	7.85E-04	<i>GLI2;NKX6-1;GLI3;NKX6-2;PAX6;DBX1</i>
67	cell fate specification involved in pattern specification	6	11	54.55	7.85E-04	<i>GLI2;NKX6-1;GLI3;NKX6-2;PAX6;DBX1</i>
68	neural tube patterning	12	34	35.29	9.64E-04	<i>WNT3A;GLI2;EN1;IFT122;GLI3;SOX17;PTCH1;PAX6;KDM2B;LRP6;FOXA1;FOXA2</i>
69	receptor clustering	11	28	39.29	9.93E-04	<i>FLNA;AGRN;NRXN1;ETV5;IFT122;DOK7;SYNGAP1;LRP4;LRP10;DLG4;CACNA1A</i>
70	temperature homeostasis	8	27	29.63	1.16E-03	<i>IL1RN;GPX1;ADRB2;HTR2A;GPX2;FTO;NR1D1;STAT3</i>
71	establishment of mitotic spindle localization	6	16	37.50	1.20E-03	<i>ARHGEF2;HTT;INSC;ESPL1;NUSAP1;NDE1</i>
72	intrinsic apoptotic signaling pathway in response to oxidative stress	6	17	35.29	1.32E-03	<i>GPX1;MAP3K5;STK3;STK24;UACA;BCL2</i>

73	negative regulation of cell proliferation	109	580	18.79	1.43E-03	<i>PIM2;DLG3;PRDX4;FOXP3;NRK;NTRK1;PTPRU;SKI;LEPRE1;CDKN2C;S100A11;REN;RBBP4;IGFBP5;SOX11;HDAC4;ING5;PELI1;SH3BP4;SPEG;SERPINE2;NCK2;CGREF1;BCL6;ROBO1;WNT5A;RARRES1;FGFRL1;CTBP1;MSX1;SFRP2;FGFR3;HTT;SLIT3;MCC;CSNK2B;RPS6KA2;JARID2;TFAP2A;GPLD1;SRF;DDR1;CDKN1A;GLI3;IGFBP3;PTK2B;STK3;MYC;TRIB1;DLC1;TP53INP1;NOTCH1;DAB2IP;PTC H1;WNK2;ROR2;ITGB1;VAX1;GDF2;PTEN;GTPBP4;PAX6;BDNF;MLL;MUC2;INPPL1;ASCL2;SF1;WT 1;ZBTB16;FOSL1;IFITM1;CEND1;KDM2B;LRP6;TESC;CDKN1B;RNF10;ATP8A2;RB1;FLT3;MEG3;PP P2R5C;BCL11B;CDKN3;VSX2;SSTR1;NR2F2;THBS1;SMAD6;GREM1;TSC2;CDH13;FOXJ1;AXIN2;ALO X15B;FLCN;MED1;TGIF1;ADCYAP1;RAX;BCL2;RBM38;BMP7;COL18A1;ADARB1;COMT;TSPO;NF2</i>
74	negative regulation of canonical Wnt signaling pathway	23	91	25.27	1.46E-03	<i>FAM123B;WWTR1;SIAH2;WNT5A;DKK2;SFRP2;MCC;ANKRD6;GLI3;SOSTDC1;STK3;SOX17;NOTCH1;DAB2IP;ROR2;TCF7L2;DKK1;LRP4;PRICKLE1;LRP10;GREM1;AXIN2;APC2</i>
75	positive regulation of glycogen biosynthetic process	6	14	42.86	1.74E-03	<i>IRS1;CIQTNF2;GCK;SORBS1;AKT1;INSR</i>
76	activation of MAPKKK activity	5	13	38.46	1.81E-03	<i>GCK;DAB2IP;MAP4K2;MAP4K1;MAP3K7IP1</i>
77	detection of mechanical stimulus involved in sensory perception	8	23	34.78	1.81E-03	<i>NTRK1;SERPINE2;SLC12A2;FYN;GRIN2B;HTR2A;ACCN1;TMC2</i>
78	cellular protein complex assembly	45	235	19.15	1.82E-03	<i>DMD;MID1IP1;WNT3A;PDE4DIP;PEX14;FMOD;NCK2;PDGFC;TPPP;ADRB2;CSNK2B;PFDN6;TAPB P;FBXO5;CADPS2;COBL;PTK2B;PTK2;NRG1;TRAF2;GSN;LZTS2;NRG3;RIC3;PSMD9;TUBA1A;FKBP 4;PXN;HSP90AA1;TMED10;GREM1;CYBA;COG4;MYH11;TUBB3;GAS7;CCDC40;UBE2S;UNC13A;FC HO1;C19orf51;CCDC114;AURKC;TUBB1;PSMG1</i>
79	neural precursor cell proliferation	18	63	28.57	1.82E-03	<i>ARX;WNT3A;DISC1;ARTN;ZEB2;ACSL6;DAGLB;GLI3;TACC2;DAGLA;RRM1;LHX5;LRP6;NCOR2;FRS 2;NDE1;PCNT;PLXNB2</i>
80	nucleotide-binding oligomerization domain containing signaling pathway	8	28	28.57	1.86E-03	<i>MAP3K7IP3;IKBKKG;IRAK1;NOD1;RELA;MAP2K6;UBE2V1;MAP3K7IP1</i>

81	endocardium development	5	12	41.67	1.91E-03	<i>ACVR1;STK3;NRG1;SOX17;NOTCH1</i>
82	protein polyubiquitination	34	174	19.54	1.91E-03	<i>UBE2A;HUWE1;PSMB2;PELI1;PSMD14;PSME4;RNF168;FBXW11;PSMB9;PARK2;PSMB1;SMURF1;UBE3C;RNF216;TNKS;TRAF2;UBE2D1;TNKS2;PSMD9;CHFR;ANAPC5;CDC16;ASB2;WWP2;MGRN1;PSMB10;CDC27;NEDD4L;BCL2;UBE2S;APC2;FZR1;UBE2V1;PSMF1</i>
83	axis elongation	9	25	36.00	2.07E-03	<i>VANGL2;WNT3A;WNT5A;SFRP2;RDH10;LRP6;MED1;TRIM28;TFAP2C</i>
84	negative regulation of cysteine-type endopeptidase activity involved in apoptotic process	16	66	24.24	2.29E-03	<i>RPS6KA3;DDX3X;HBXIP;MAL;SIAH2;PAK2;GPX1;SFRP2;FNIP1;DNAJB6;INTS1;PAX2;PRDX5;AKT1;THBS1;MAP2K5</i>
85	epithelial cell fate commitment	7	17	41.18	2.35E-03	<i>ARX;ACVR1;FGFR3;HOXA13;NOTCH1;JAG2;NR2F2</i>
86	mitotic cell cycle	113	671	16.84	2.79E-03	<i>PIM2;FLNA;STAG2;PPP1R12B;SDCCAG8;ARHGEF2;PHF13;ENSA;RCC2;CDKN2C;PSMB2;JTB;TPR;CENPL;RBBP4;EML4;ALMS1;ACVR1;SPTBN1;PSMD14;NCAPH;PSME4;STAG1;MAP4;NUP210;RFC1;CAMK2D;PPP3CA;MLF1IP;HTT;PLK2;FBXL7;CSNK2B;DAXX;PSMB9;KIFC1;FBXO5;NUP43;NEDD9;CDKN1A;PSMB1;KIF25;MAD1L1;MCM7;YWHAG;ARHGEF10;NSMCE2;DLC1;TNKS;TAF2;LZTS2;ITGB1;TUBGCP2;CAMK2G;PPP2R2D;PTEN;UBE2D1;CCND1;BRSK2;INSC;RRM1;CKAP5;BANF1;CDCA5;HINFP;NCAPD2;EPS8;ESPL1;PSMD9;CHFR;TUBA1A;AAAS;ANKLE2;DYNLL1;ANAPC5;BCAT1;PPP1R12A;CDKN1B;RBI;NEK3;CDC16;DYNC1H1;HSP90AA1;CDKN3;C15orf23;NUSAP1;GINS2;E2F4;CDH13;NDE1;JMJD5;TUBB3;PSMB10;ZNF830;MYH10;TEX14;TADA2A;CDC27;NFATC1;CTDP1;SEH1L;UBE2S;APC2;B9D2;FZR1;KIAA0892;PLK5P;AURKC;RBL1;DSN1;PSMF1;PCNT;TRIOBP</i>
87	negative regulation of muscle cell apoptotic process	8	23	34.78	2.95E-03	<i>SFRP2;HMGCR;PTK2B;NRG1;LRP6;IGF1R;ADCYAP1;BMP7</i>
88	phospholipid efflux	4	11	36.36	3.55E-03	<i>APOA1;APC2;ABCA7;ABCG1</i>
89	regulation of energy homeostasis	4	10	40.00	4.31E-03	<i>SGIP1;PASK;NR1D2;FLCN</i>

90	cellular cation homeostasis	63	383	16.45	4.37E-03	<i>BCAP31;ABCB7;ARF1;RYR2;DISC1;SLC9A1;GNB1;ATP6V1B1;SLC8A1;ATP6V1C2;TRPM8;TTC7A;RAB7A;PROK2;TNNC1;XCR1;ITPR1;STIM2;PDE6B;NPY2R;NR3C2;PDE6A;ITPR3;CFTR;TAC1;TFR2;ATP6V0A4;GCK;PTK2B;MYC;SLC39A14;KCNMA1;ITGB1;CDH23;GDF2;CBARA1;CALCA;DRD4;SLC39A13;CCKBR;RIC3;LRP6;CACNA1C;TM6IM6;HTR2A;GPR12;EDNRB;SLC8A3;SLC24A4;NPTN;JPH3;HMOX2;DLG4;ADCYAP1;NEDD4L;BCL2;CACNA1A;RYR1;TBXA2R;TNNI3;LPAR2;SLC4A11;SLC9A8</i>
91	regulation of sodium ion transport	14	51	27.45	4.85E-03	<i>DMD;SERPINE2;MAGI1;CAMK2D;ADRB2;UTRN;CNKSR3;WNK2;DRD4;TESC;FGF14;AKT1;NEDD4L;SIK1</i>
92	negative regulation of phosphatidylinositol 3-kinase signaling	5	12	41.67	4.94E-03	<i>SERPINE2;DAB2IP;PTEN;TSC2;PIK3IP1</i>
93	mitotic chromosome condensation	5	14	35.71	4.96E-03	<i>PHF13;NCAPH;CDCA5;NCAPD2;NUSAP1</i>
94	negative regulation of reproductive process	8	28	28.57	5.76E-03	<i>PRDX4;WNT5A;ZP3;SF1;WT1;CDKN1B;BMP7;TPST2</i>
95	positive regulation by host of viral transcription	4	11	36.36	7.12E-03	<i>ZNF639;SNW1;SMARCA4;EP300</i>
96	beta-amyloid metabolic process	4	12	33.33	7.15E-03	<i>REN;MME;TMED10;UNC13A</i>
97	protein homotrimerization	5	15	33.33	8.74E-03	<i>SKI;TRPM8;SKIL;TRAF2;HSF4</i>
98	transepithelial transport	4	13	30.77	9.26E-03	<i>SLC12A2;GPLD1;CFTR;RHCG</i>
99	polysaccharide biosynthetic process	9	37	24.32	9.76E-03	<i>UGP2;MAT2B;NDST1;GCK;EXT1;PPP1R3C;AKT1;GLT25D1;HAS1</i>
100	citrulline metabolic process	4	11	36.36	1.44E-02	<i>DDAH1;HTT;DDAH2;ALDH18A1</i>